



**PATENT**  
U.S. Appln. Ser. No.: 09/410,484  
Attorney Docket No. NATNUT-03972

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


In re Application of: Jan Wadstein *et al.*  
Serial No.: 09/410,484  
Filed: 09/30/99  
Entitled: **Method Of Treating Hypertension And Reducing Serum Lipase Activity**  
Group No.: 1614  
Examiner: Webman

**Declaration of Asgeir Sæbo**

Assistant Commissioner for Patents  
Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231

Dated: 4-25-07 By: 

I, Asgeir Sæbo, state as follows:

1. My present position is Research Director, Natural ASA.
2. It is my understanding that the Examiner has stated the following in the Office Action dated January 25, 2007:

First, Kawamura *et al.* provide a nexus teaching between weight loss in hypertensive patients and lowering of blood pressure. It remains obvious to one of ordinary skill in the art that the method of Cook *et al.* can lower blood pressure via weight loss. The Examiner did not assert that CLA would have a positive or negative on hypertension like ephedrine as submitted by Applicant. The Examiner asserts that weight loss is directly related to lowering of blood pressure, as supported by Kawamura *et al.*, and CLA can be used to effect weight loss as taught by Cook *et al.* Secondly, one of ordinary skill in the art would have a reasonable expectation of success because of the nexus teaching of Kawamura *et al.*

3. When a biologically active agent, such as CLA, is administered to a subject there can be a variety of effects. Just because CLA causes weight loss does not also mean that it would reduce hypertension. A person of skill in the art would not reasonable expect CLA to reduce hypertension for two reasons.

4. First, CLA has been shown to elevate the level of F2-isoprostane. Taylor et al., *Conjugated Linoleic Acid Impairs Endothelial Function, Arteriosclerosis, Thrombosis, and Vascular Biology* 26(2), 307-312 (2006)(attached at Tab 1). F2-isoprostanes have a vasoconstrictive effect. Cracowski et al., *Cardiovascular pharmacology and physiology of the isoprostanes, Fundamental & Clinical Pharmacology* 20(5): 417-427 (2006)(attached at Tab 2). Taken together, it should be expected that administration of CLA would result in an increase in blood pressure.

5. Second, administration of other agents known to be effective for weight loss can result in increased hypertension. Ephedrine, a commonly used, biologically active weight loss supplement is one such example. As established in Haller and Benowitz, *Adverse Cardiovascular and Central Nervous System Events Associated with Dietary Supplements Containing Ephedra Alkaloids*, *New England J. Med.* 343(25):1833-1838 (2000)(attached at Tab 3), ephedrine can cause an increase in hypertension.

6. The Examiner's argument that it would be obvious to use CLA to decrease hypertension because CLA administration also causes weight loss lacks scientific merit. How an agent such as CLA acts in the body is complex. Whether CLA causes an increase or decrease in hypertension, or has no effect at all, is determined by a variety of factors that have no relation to weight loss. It is not scientifically valid to draw a conclusion that because an agent causes weight loss, it can also be expected to decrease hypertension. The references cited by the Examiner contain no data that can be interpreted in this manner.

7. I further declare that all statement made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of title 18 of the United States

Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



Asgeir Sæbo

Date: March 26th. 2007

MAIN Ser CISTI/ICIST NRC/CNRC  
RM1 MAIN Ser  
F981 0767-3981  
v. 20 Received on: 06-10-25  
no. 5 Fundamental & clinical  
2006 Oct pharmacology.

ISSN 0767-3981 (print)  
ISSN 1472-8206 (online)

# *Fundamental & Clinical* Pharmacology

REVIEW  
ARTICLECardiovascular pharmacology and  
physiology of the isoprostanesJean-Luc Cracowski<sup>a\*</sup>, Thierry Durand<sup>b</sup><sup>a</sup>Laboratoire de Pharmacologie, Inserm ESPRI, HP2 EA 3745, Faculté de Médecine de Grenoble, France<sup>b</sup>UMR CNRS, 5074, Faculté de Pharmacie, Université Montpellier 1, Montpellier, France

## Keywords

atherosclerosis,  
hypertension,  
ischemia,  
isoprostane,  
lipid peroxidation,  
vasoconstrictionReceived 2 March 2006;  
revised 27 April 2006;  
accepted 13 June 2006\*Correspondence and reprints:  
jean-luc.cracowski@ujf-  
grenoble.fr

## ABSTRACT

F<sub>2</sub>-isoprostanes are a complex family of compounds produced from arachidonic acid via a free radical-catalyzed mechanism. Their quantification as a pathophysiological biomarker provides a unique opportunity to investigate lipid peroxidation in vascular diseases. Their measurement also provides an interesting biomarker for the rational dose selection of antioxidants in vascular diseases where oxidative stress might be involved. In addition to their use as biomarkers, some isoprostanes possess a biological activity. The 15-series F<sub>2</sub>- and E<sub>2</sub>-isoprostanes mediate vasoconstriction in different vascular beds and species. In addition, 15-F<sub>2t</sub>-IsoP induces smooth muscle cells mitogenesis and monocyte adhesion to endothelial cells. The data available supports but does not prove the hypothesis that isoprostanes are involved in vascular physiology and pathogenesis.

## INTRODUCTION


Isoprostanes are a complex family of compounds produced from arachidonic acid via a free radical-catalyzed mechanism. In vitro generation of auto-oxidation products derived from polyunsaturated fatty acids was described more than 30 years ago [1,2]. However, the first demonstration that these compounds were produced in humans was shown in 1990 by Morrow et al. [3], who reported the discovery of prostaglandin-F<sub>2</sub>-like compounds, termed F<sub>2</sub>-isoprostanes, generated by free radical-induced peroxidation of arachidonic acid. Since that time, F<sub>2</sub>-isoprostanes have been used extensively as clinical markers of lipid peroxidation in cardiovascular disorders. These compounds are not only biomarkers. Indeed, the 15-series F<sub>2</sub>- and E<sub>2</sub>-isoprostanes possess a pharmacological activity on the blood vessels.

ISOPROSTANE STRUCTURE AND  
SYNTHESIS

Depending on which of the labile hydrogen atoms of arachidonic acid is first abstracted by free radicals, three

initial arachidonoyl radicals can be formed following free radical attack. These radicals form four prostaglandin-H<sub>2</sub>-like compounds that can then be fully reduced to form four prostaglandin F<sub>2 $\alpha$</sub>  regioisomers (Figure 1), or rearranged to form prostaglandin E<sub>2</sub> and D<sub>2</sub> regioisomers. Two mechanisms, based on the formation of a 'dioxetane' intermediate, via a 4-*exo*-cyclization or a  $\beta$ -fragmentation followed by successive 5-*exo*-cyclizations have been proposed recently for the formation of these compounds [4]. Because each F<sub>2</sub>-isoprostane regioisomer comprises eight diastereoisomers, 64 different F<sub>2</sub>-isoprostanes can be generated.

Isoprostanes were formerly named according to the prostaglandin F<sub>2 $\alpha$</sub>  chemical structure. They differ from prostaglandins by the *cis*-stereochemistry of the five-membered ring junction instead of the *trans*-stereochemistry of the prostaglandin F<sub>2 $\alpha$</sub> . Because the first isoprostanes described were the 15-series, they were formerly named according to this major difference, the first isoprostane being named 8-*iso*-prostaglandin F<sub>2 $\alpha$</sub>  or 8-*epi*-prostaglandin F<sub>2 $\alpha$</sub> . However, such a nomenclature does not allow the differentiation of the numerous isomeric structures. Two nomenclatures were proposed



**Figure 1** The isoprostane (IsoP) pathway. Free radical attack of arachidonic acid results in the formation of arachidonoyl radicals, which, following peroxidation, form four prostaglandin-H<sub>2</sub>-like compounds that can then be fully reduced to form four prostaglandin F<sub>2α</sub> regioisomers [those of the 15-series (type III), 8-series (type IV), 12-series (type V) and 5-series (type VI)], or rearranged to form prostaglandin E<sub>2</sub> and D<sub>2</sub> regioisomers. Each regioisomer comprises eight diastereoisomers and so 64 different F<sub>2</sub>-isoprostanes can be generated.

recently, both of which enable an easy differentiation of the isoprostane isomers. Taber et al. [5] nomenclature was filed with the Eicosanoid Nomenclature Committee, and approved by the International Union of Pure and Applied Chemistry. Rokach et al. [6] also proposed a nomenclature that enables the differentiation of the regioisomers. In 1997, this nomenclature was modified to be applicable to isoprostane-like compounds derived from eicosapentaenoic and docosahexaenoic acid. The concomitant use of these three different nomenclatures is confusing for the nonspecialist, and we propose that the old nomenclature (e.g. 8-*iso*-prostaglandin F<sub>2α</sub>) be definitively abandoned, and that Taber's nomenclature be encouraged. The different nomenclatures used to name the main isoprostanes are given in Figure 2.

Several *in vitro* studies have suggested a cyclooxygenase (COX)-dependent formation of 15-F<sub>2t</sub>-IsoP [7–9]. An efficient *in vivo* production of 15-F<sub>2t</sub>-IsoP through the COX pathway would reduce its accuracy as

a valid marker of lipid peroxidation. In contrast to the *in vitro* data, clinical studies clearly showed that COX inhibition was unable to decrease the formation of F<sub>2</sub>-isoprostanes in healthy subjects as well as patients, suggesting that F<sub>2</sub>-isoprostanes are formed via a non-COX-dependent mechanism *in vivo* [10–14]. Furthermore, in conditions of increased COX-2 expression following intravenous lipopolysaccharide challenge, the formation of 15-F<sub>2t</sub>-IsoP and of 5-series isomers was not altered by COX inhibitors in healthy volunteers, whereas prostanoid production was decreased, further suggesting a COX-independent pathway of F<sub>2</sub>-isoprostane synthesis [15]. Finally, an *in vivo* COX-dependent formation of iPF<sub>2</sub>-III has been shown in the rat but not in humans [16]. Altogether, these data suggest that although a COX-dependent formation can be demonstrated *in vitro*, this does not occur *in vivo* in humans, meaning that 15-F<sub>2t</sub>-IsoP as well as the 5-series isomers can be used as biomarkers of lipid peroxidation *in vivo*.



Chemical structure	Former nomenclature	Taber's nomenclature	Rokach's nomenclature
	8-iso-PGF <sub>2α</sub>	15-F <sub>2t</sub> -IsoP	iPF <sub>2α</sub> -III
	8-iso-PGE <sub>2</sub>	15-E <sub>2t</sub> -IsoP	iPE <sub>2</sub> -III
	2,3-dinor-5,6-dihydro-8-iso-PGF <sub>2α</sub>	2,3-dinor-5,6-dihydro-15-F <sub>2t</sub> -IsoP	2,3-dinor-5,6-dihydro-iPF <sub>2α</sub> -III
	Not available	5-F <sub>2t</sub> -IsoP	iPF <sub>2α</sub> -VI
	Not available	5-F <sub>2t</sub> -IsoP	8,12-iso-iPF <sub>2α</sub> -VI
	8-iso-PGF <sub>3α</sub>	15-F <sub>3t</sub> -IsoP	iPF <sub>3α</sub> -III

Figure 2 Nomenclature of the isoprostanes.

## ISOPROSTANE QUANTIFICATION

Quantification of F<sub>2</sub>-isoprostanes is used as a reliable marker of lipid peroxidation *in vivo* [17], and several methods are currently used [18] including gas chromatography (GC)–mass spectrometry (MS), which might be associated with an immunoaffinity extraction, GC–tandem MS, and liquid chromatography–tandem MS. These methods are reviewed in detail elsewhere [19]. They are specific but their cost and technology limit their routine use. Measurement of urinary 15-F<sub>2t</sub>-IsoP by radioimmunoassay has been validated and constitutes a valid and easier alternative to GC–MS [20]. Enzyme immunoassays have also been developed to measure levels of F<sub>2</sub>-isoprostanes but the antibodies used have not been tested for cross-reactivity with the numerous F<sub>2</sub>-isoprostane isomers and their metabolites. The results obtained using enzyme immunoassays sometimes differ from those obtained using GC–MS assays and therefore immunoassays should be considered as semi-quantitative indices of F<sub>2</sub>-isoprostanes.

## VASCULAR PHARMACOLOGY OF THE ISOPROSTANES

Isoprostanes are formed *in situ* on phospholipids, at sites of free radical generation. Once released from cell

membranes by phospholipases, isoprostanes circulate in the plasma in free forms and are therefore susceptible to activate membrane receptors. Most studies have focused on the biological activity of 15-F<sub>2t</sub>-IsoP, the first isoprostane commercially available. 15-F<sub>2t</sub>-IsoP is a vasoconstrictor in most species and vascular beds, both *in vitro* and *in vivo*, following intravenous administration (see [21,22] for full reviews). These constrictor properties are not specific to the blood vessels and have been demonstrated in the lymphatic vessels, the bronchi, the gastrointestinal tract and the uterus. In addition, it stimulates mitogenesis in uterine vascular smooth muscle cells [23]. The available data strongly suggest that the effects of 15-F<sub>2t</sub>-IsoP on blood vessels are mediated by the activation of the TP receptors (thromboxane A<sub>2</sub>/prostaglandin H<sub>2</sub> receptors), acting as a full or partial agonist [24,25], although some responses including mitogenesis appear to be at least in part TP receptor independent. The existence of a specific isoprostane receptor has been suggested but remains to be elucidated [26]. In addition, preliminary data suggest that isoprostanes, as well as their precursor arachidonic acid, are other lipid ligands for the peroxisome proliferator activated receptors (PPAR) [27].

The effects of 15-F<sub>2t</sub>-IsoP on platelets are complex. When incubated with subthreshold concentrations of ADP, thrombin, collagen and arachidonic acid, 15-F<sub>2t</sub>-IsoP causes irreversible platelet aggregation, dependent




Figure 3 Schematic representation of the pharmacological activities of the isoprostane 15-F<sub>2t</sub>-IsoP on the interface blood vessels. COX, cyclo-oxygenase; TXA<sub>2</sub>, thromboxane A<sub>2</sub>; PGI<sub>2</sub>, prostacyclin; NO, nitric oxide; TP, prostaglandin H<sub>2</sub>/thromboxane receptor; IPR, specific isoprostane receptor; PLC, phospholipase C; ET-1, endothelin-1; ECE, endothelin conversion enzyme. For a better comprehension, the thickness of the arrows are correlated to the scientific evidence of these mechanisms. Such mechanisms are likely to differ within species, as well as within the vessel types.

on thromboxane generation, while 15-F<sub>2t</sub>-IsoP alone induces weak, reversible aggregation, only at high concentrations [28]. As 15-F<sub>2t</sub>-IsoP is a partial agonist at the prostanoid TP receptor on platelets, it might inhibit the pro-aggregatory effects of TP receptor stimulation. Indeed, in human whole blood, 15-F<sub>2t</sub>-IsoP is anti-aggregatory [29]. Several authors suggested that increased isoprostane formation is one of the factors involved in aspirin resistance, but a full demonstration of this hypothesis is not available to date [30–33].

15-F<sub>2t</sub>-IsoP-induced contraction is modulated by the endothelium through the release of NO, i.e. endothelium removal increases 15-F<sub>2t</sub>-IsoP contraction [21]. In addition, 15-F<sub>2t</sub>-IsoP induces both thromboxane A<sub>2</sub> and endothelin-1 release from endothelial cells (Figure 3). In comparison with the huge data available for 15-F<sub>2t</sub>-IsoP, few are available for other isomers. Nevertheless, other isoprostanes belonging to the 15 series of the F-family isoprostanes, such as 9-epi-15-F<sub>2t</sub>-IsoP and 15-epi-15-F<sub>2t</sub>-IsoP are biologically active, although less potent than 15-F<sub>2t</sub>-IsoP [21]. The 5-series and 15-series F<sub>2</sub>-isoprostanes are produced in approximately equal amounts *in vivo* whereas the 8-series and 12-series F<sub>2</sub>-isoprostanes are produced in lower amounts [34]. In human urine and plasma, the 5-series (e.g. 5-F<sub>2t</sub>-IsoP and 5-F<sub>2c</sub>-IsoP) was found to be the most abundant F<sub>2</sub>-isoprostanes [35]. Both the 15-series and the 5-series are easily detectable in human urine and plasma. However, in contrast to the

15-series F<sub>2</sub>-isoprostanes, the 5-series F<sub>2</sub>-isoprostanes have no vasomotor effect in different species and vascular beds [36] and as such are unlikely to be involved in the pathogenesis of vascular diseases. In addition to the vasoconstrictor and mitogenic effects, 15-F<sub>2t</sub>-IsoP and 15-E<sub>2t</sub>-IsoP induce monocyte adhesion to endothelial cells [37,38], whereas 15-F<sub>2t</sub>-IsoP is a specific activator of rapid neutrophil adhesion [39]. Furthermore, 15-F<sub>2t</sub>-IsoP induces cerebral endothelial cell death [40]. Endothelial cells are one of the first targets of oxidative stress in atherogenesis and ischemia–reperfusion injury. Whether isoprostanes may be one of pathogenic mediators remains to be tested.

Compared with the F<sub>2</sub>-isoprostanes, E<sub>2</sub>-isoprostanes are more potent *in vitro*. 15-E<sub>2t</sub>-IsoP is more potent than 15-F<sub>2t</sub>-IsoP in systemic and pulmonary vessels, its contraction being mediated through TP receptor, and EP<sub>3</sub> receptor activation in the pulmonary vasculature [41,42]. In addition, 15-E<sub>2t</sub>-IsoP may induce a relaxation through EP receptors [43]. However, because no data are available concerning the production of E<sub>2</sub>-isoprostanes in cardiovascular disorders, it is premature to conclude concerning the potential role of such compounds in cardiovascular pathogenesis.

One should keep in mind that Morrow et al. showed [44] that A<sub>2</sub>-isothromboxanes are formed *in vivo*. Due to the inherent instability of the thromboxane A<sub>2</sub> ring, no data concerning the vascular effects of A<sub>2</sub>-isothromb-



oxanes are available. However, regarding the potency of thromboxane A<sub>2</sub>-induced contractions, studies using stable A<sub>2</sub>-isothromboxanes analogues are awaited with interest.

To date, the metabolism of 15-F<sub>2t</sub>-IsoP leads to two major metabolites in humans: 2,3-dinor-15-F<sub>2t</sub>-IsoP and 2,3-dinor-5,6-dihydro-15-F<sub>2t</sub>-IsoP [45,46]. The metabolite 2,3,4,5-tetranor-13,14-dihydro-15-keto-15-F<sub>2t</sub>-IsoP [47] was identified as the major metabolite in rabbits but there is no evidence that such a metabolite is produced in humans. Although most prostanoid metabolites are biologically inactive, surprisingly, a recent report showed that 2,3-dinor-5,6-dihydro-15-F<sub>2t</sub>-IsoP exhibits contraction that is comparable with that of 15-F<sub>2t</sub>-IsoP in porcine brain microvessels [48]. By contrast, unlike 15-F<sub>2t</sub>-IsoP, neither 2,3-dinor-5,6-dihydro-15-F<sub>2t</sub>-IsoP nor 2,3-dinor-15-F<sub>2t</sub>-IsoP had any constrictor or dilator effects on the rat thoracic aorta [49]. Such disparate observations need to be further investigated in different species and vascular beds.

Recently, isoprostane-like compounds derived from eicosapentaenoic and docosahexaenoic acids have been discovered *in vivo* [50–52]. Among the F<sub>3</sub>-isoprostanes formed, 15-F<sub>3t</sub>-IsoP possesses either no biological effect or might induce a weak relaxation in human airways. Preliminary data suggest that F<sub>4</sub>-neuroprostanes possess no vascular effects.

## ISOPROSTANES AS A BIOMARKER OF LIPID PEROXIDATION IN VASCULAR DISEASES

Isoprostanes have been measured in biological fluids such as urine, plasma, exhaled breath condensate, bronchoalveolar lavage fluid, bile, cerebrospinal, seminal and pericardial fluids. They are also detectable in normal tissues, including umbilical cords [53]. The main advantage of urinary measurements is that both 15-F<sub>2t</sub>-IsoP and 5-F<sub>2t</sub>-IsoP are not formed *ex vivo* by auto-oxidation in urine, unlike in plasma samples.

Cigarette smoking was one of the first conditions in which an increase in F<sub>2</sub>-isoprostane levels was demonstrated [54]. This increase is reduced after 2 weeks of abstinence from smoking [14,54] and almost reaches the values of nonsmokers 4 weeks after quitting smoking [55]. Short-term cigarette smoking increases exhaled breath condensate F<sub>2</sub>-isoprostane concentrations [56], but not plasma levels of F<sub>2</sub>-isoprostane [54]. Restarting smoking after quitting and passive smoking are associated with an increase in plasma levels of F<sub>2</sub>-isoprostane

[57,58]. Interestingly, 15-F<sub>2t</sub>-IsoP concentrations were approximately twice as high in umbilical cords from newborn babies of smoking mothers compared with those of nonsmoking mothers [53]. Together, these data provide evidence that cigarette smoking is associated with a chronic increased lipid peroxidation *in vivo*.

The measurement of isoprostanes in biological fluids has prompted clinical investigations on the pathophysiological role of lipid peroxidation in cardiovascular diseases (Table I). Among the biological fluids available, most studies were performed on urine because of the non-invasiveness of the procedure and the lack of artifactual generation. A strong link between lipid peroxidation and vascular diseases associated with ischemia–reperfusion, atherosclerosis and inflammation has been suggested by the elevated levels of lipid peroxidation observed in such diseases.

In addition to being a pathophysiological marker, the quantification of F<sub>2</sub>-isoprostanes might represent a prognostic marker. Indeed, Schwedhelm *et al.* [59] showed in a case–control study that urinary 15-F<sub>2t</sub>-IsoP level was a strong independent concentration-dependent risk marker of coronary heart disease. In addition, there is a relationship between plasma F<sub>2</sub>-isoprostanes and early development of coronary artery calcifications [60]. There are currently no published clinical studies aimed at testing isoprostanes as a long-term prognostic marker, with strong endpoints such as mortality or morbidity, but cohort studies are on-going.

## ISOPROSTANES: EMERGING ROLE IN VASCULAR PHYSIOLOGY AND DISEASE?

An important issue to resolve is whether the same effects observed *in vitro* are observed consistently *in vivo* at physiological concentrations and whether these effects contribute to pathological states *in vivo*. Basal plasma concentrations of 15-F<sub>2t</sub>-IsoP have been found to range from approximately 10<sup>–10</sup> to 5 × 10<sup>–10</sup> mol L<sup>–1</sup> in plasma samples. These concentrations are unlikely to induce a systemic vasoactive effect considering the EC<sub>50</sub> values of 15-F<sub>2t</sub>-IsoP observed *in vitro* [21,61]. However, F<sub>2</sub>-isoprostanes are released at the site of free radical injury and then diluted in the circulation and therefore local concentrations might be sufficiently high to induce regional vasoconstriction. The concentrations of 15-F<sub>2t</sub>-IsoP and 5-F<sub>2t</sub>-IsoP are increased markedly in the coronary sinus following coronary angioplasty [62]. However, 15-F<sub>2t</sub>-IsoP concentrations are in the

Table 1 F<sub>2</sub>-isoprostane quantification in human cardiovascular diseases.

Disease	Isoprostanes quantified	Tissue or biological fluid tested	Method	Results in comparison with a control group	References
Essential hypertension	15-F <sub>2t</sub> -IsoP	Urine	EIA and GC-MS	NSD	[86-88]
Hypertensive patients with renovascular disease	15-F <sub>2t</sub> -IsoP	Urine	EIA	Increased	[86]
Heart failure	15-F <sub>2t</sub> -IsoP	Urine, pericardial fluid	LC-MS-MS and EIA	Increased	[89-92]
Atherosclerosis	15-F <sub>2t</sub> -IsoP and 5-F <sub>2t</sub> -IsoP	Atherosclerotic lesions from carotid endarterectomy	GC-MS and RIA	Increased	[93-95]
Ruptured abdominal aortic aneurysm	15-F <sub>2t</sub> -IsoP	Plasma	EIA	Increased	[96]
Stable coronary heart disease	15-F <sub>2t</sub> -IsoP	Urine	GC-MS and RIA	NSD	[97,98]
Unstable angina	15-F <sub>2t</sub> -IsoP	Urine	RIA	Increased	[98]
Reperfusion following myocardial infarction and cardiopulmonary bypass	15-F <sub>2t</sub> -IsoP and 5-F <sub>2t</sub> -IsoP	Urine	GC-MS	Increased	[97,99]
Coronary angioplasty	15-F <sub>2t</sub> -IsoP and 5-F <sub>2t</sub> -IsoP	Urine and coronary sinus	GC-MS	Increased	[62,99]
Systemic sclerosis (scleroderma)	15-F <sub>2t</sub> -IsoP and F <sub>2t</sub> -isoprostane metabolites	Urine	GC-MS AND EIA	Increased	[100-104]
Antiphospholipid antibodies syndrome	15-F <sub>2t</sub> -IsoP and 5-F <sub>2t</sub> -IsoP	Urine	GC-MS and EIA	Increased	[105,106]
Raynaud's phenomenon	15-F <sub>2t</sub> -IsoP	Urine	GC-MS	NSD	[101,104]
Pulmonary hypertension	15-F <sub>2t</sub> -IsoP	Urine	GC-MS	Increased	[107]
Acute ischemic stroke	15-F <sub>2t</sub> -IsoP	Urine	RIA	No variation over 72 h	[108]
Migraine	15-F <sub>2t</sub> -IsoP	Urine	RIA	NSD	[109]
Preeclampsia	15-F <sub>2t</sub> -IsoP and 5-F <sub>2t</sub> -IsoP	Plasma, urine and saliva and placental tissue	GC-MS and EIA	Conflicting results among studies	[110-116]

EIA, enzyme immunoassay; GC-MS, gas chromatography-mass spectrometry; LC-MS-MS, liquid chromatography-tandem mass spectrometry; NSD, not significantly different; RIA, radioimmunoassay.

nanomolar range, and thus unlikely to contribute to epicardial coronary artery vasoconstriction [61,63].

No specific inhibition of 15-F<sub>2t</sub>-IsoP or other isoprostanes vascular effects can currently be achieved. However, TP receptor antagonists but not aspirin are effective in atherosclerosis inhibition in apo E knock-out mice, showing that TP receptors blockade by S18886 is effective by a mechanism independent of platelet-derived thromboxane A<sub>2</sub> [64], whereas isoprostanes suppression with vitamin E retards atherogenesis in the same animal model [65]. Similarly, TP receptor antagonism by L670596, but not COX-2 inhibition prevented pulmonary hypertension and endothelin-1 upregulation in 60% O<sub>2</sub>-mediated pulmonary hypertension in newborns rats [66]. In addition to these animal data, a recent study showed that in patients suffering from coronary artery disease, S18886, a TP receptor antagonist improved acetylcholine-induced and flow-mediated vasodilation in patients treated with aspirin [67]. An hypothesis is that endogenous TP receptor activation induced by 15-F<sub>2t</sub>-IsoP or other isoprostanes may be involved in the COX-independent effects of TP receptors antagonists [68]. However, because TP receptors share other endogenous ligands such as prostaglandin H<sub>2</sub> or hydroxyeicosatetraenoic acids (HETEs), such data give strength to the hypothesis that isoprostanes are involved in the vascular physiology and pathogenesis, but does not enable a definitive conclusion. Given that many isomeric isoprostanes exist, one should not focus only on 15-F<sub>2t</sub>-IsoP. Other 15-series F<sub>2</sub>-isoprostanes are biologically active, as well as E<sub>2</sub>-isoprostanes [22] and large field of investigations are still unexplored.

### ISOPROSTANES AS A PHARMACOLOGICAL TOOL FOR DRUG EVALUATION

In the past decade, most attention has focused on the effect of an antioxidant therapeutic strategy, including the use of vitamin E, in cardiovascular and nephrological diseases, with mixed results. Measurement of F<sub>2</sub>-isoprostanes currently represents a valuable pharmacological tool for the evaluation of antioxidant therapy, and should be used in the rational selection of antioxidant dosages. Vitamin E supplementation induced a reduction of urinary 15-F<sub>2t</sub>-IsoP levels in patients with cystic fibrosis [69], type 2 diabetes [11] and homozygous homocystinuria [70], but not in patients with systemic sclerosis [71]. In addition, such a reduction was dose dependent in hypercholesterolemic patients [10]. The

vitamin E-dependent reduction in the concentrations of F<sub>2</sub>-isoprostane was observed in clinical conditions of enhanced oxidative stress. By contrast, supplementation with vitamin E had no effects on F<sub>2</sub>-isoprostane levels in either moderate cigarette smokers [72], or healthy adults [73]. In the latter studies, the supplementation was associated with a significant dose-dependent increase in circulating concentrations of vitamin E. In addition, vitamin E supplementation in cigarette smokers on a high polyunsaturated fatty acid diet caused an increase in the plasma levels of F<sub>2</sub>-isoprostane [74]. Together, these studies suggest that vitamin E supplementation has antioxidant effects in patient populations that are characterized by high rates of lipid peroxidation. Patrignani et al. [72] hypothesized that the basal rate of lipid peroxidation may be an important determinant of the response to vitamin E supplementation, and could explain the variable effects of vitamin E supplementation in large clinical trials. Several studies favor such a hypothesis. Oral treatment with raxofelast, a vitamin-E-like antioxidant, induced a significant reduction of plasma concentrations of 15-F<sub>2t</sub>-IsoP in type 2 diabetes but had no effect in healthy subjects [75]. In addition, vitamin C supplementation reduced urinary 15-F<sub>2t</sub>-IsoP levels in patients with stroke [76], and chronic alcoholic liver disease but not in patients with hepatitis C cirrhosis, in whom endogenous vitamin C and E concentrations did not significantly differ compared with controls [77]. Furthermore, vitamin C did not decrease urinary F<sub>2</sub>-isoprostane and metabolite levels in healthy young women [78], and in young subjects with a limited history of cigarette smoking [79]. Together, these data strengthen the need to incorporate the measurement of surrogate end-points such as F<sub>2</sub>-isoprostanes in large-scale antioxidant clinical trials.

In addition to drug evaluation, F<sub>2</sub>-isoprostane measurement could be used to test the antioxidant properties of the diet. F<sub>2</sub>-isoprostane levels were decreased following supplementation with eicosapentaenoic acid or docosahexaenoic acid [80], fish meals in diabetic patients [81], olive oil [82], soy-containing isoflavone [83], gazpacho [84], and flavanol-rich cocoa [85].

### CONCLUSION

Isoprostanes are a complex family of compounds produced from arachidonic acid via a free radical-catalyzed mechanism. Some isoprostanes induce vasoconstriction, mitogenesis and monocyte adhesion. The quantification of F<sub>2</sub>-isoprostanes as a pathophysiological biomarker

provides a unique opportunity to investigate lipid peroxidation in vascular diseases. Their measurement provides an interesting biomarker for the rational dose selection of antioxidants in vascular diseases where oxidative stress might be involved. The data available supports but does not prove the hypothesis that isoprostanes are involved in vascular physiology and pathogenesis.

## REFERENCES

- Nugteren D.H., Vonkeman H., Van Drop D.A. Non-enzymatic conversion of all-cis 8,11,14-eicosatrienoic acid into prostaglandin E<sub>1</sub>. *Rec. Trav. Chim.* (1967) 86 1237–1245.
- Pryor W.A., Stanley J.P., Blair E. Autoxidation of polyunsaturated fatty acids: II. A suggested mechanism for the formation of TBA-reactive materials from prostaglandin-like endoperoxides. *Lipids* (1976) 11 370–379.
- Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., Roberts L.J. A series of prostaglandin F<sub>2</sub>-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. *Proc. Natl. Acad. Sci. U. S. A.* (1990) 87 9383–9387.
- Yin H., Havrilla C.M., Gao L., Morrow J.D., Porter N.A. Mechanisms for the formation of isoprostane endoperoxides from arachidonic acid. 'Dioxetane' intermediate versus beta-fragmentation of peroxy radicals. *J. Biol. Chem.* (2003) 278 16720–16725.
- Taber D.F., Morrow J.D., Robert L.J., II A nomenclature system for the isoprostanes. *Prostaglandins* (1997) 53 63–67.
- Rokach J., Khanapure S.F., Hwang S.W., Adiyaman M., Lawson J.A., Fitzgerald G.A. Nomenclature of isoprostanes: a proposal. *Prostaglandins* (1997) 54 853–873.
- Patrignani P., Santini G., Panara M.R. et al. Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclo-oxygenase-dependent F<sub>2</sub>-isoprostane formation. *Br. J. Pharmacol.* (1996) 118 1285–1293.
- Pratico D., Lawson J.A., Fitzgerald G.A. Cyclooxygenase-dependent formation of the isoprostane, 8-epi-prostaglandin F<sub>2α</sub>. *J. Biol. Chem.* (1995) 270 9800–9808.
- Jourdan K., Mitchell J., Evans T. Release of isoprostanes by human pulmonary artery in organ culture: a cyclo-oxygenase and nitric oxide dependent pathway. *Biochem. Biophys. Res. Commun.* (1997) 233 668–672.
- Davi G., Alessandrini P., Mezzetti A. et al. In vivo formation of 8-epi-prostaglandin F<sub>2α</sub> is increased in hypercholesterolemia. *Arterioscler. Thromb. Vasc. Biol.* (1997) 17 3230–3235.
- Davi G., Ciabattini G., Consoli A. et al. In vivo formation of 8-iso-prostaglandin F<sub>2α</sub> and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. *Circulation* (1999) 99 224–229.
- Dworski R., Murray J., Roberts L.I. et al. Allergen-induced synthesis of F<sub>2</sub>-isoprostanes in atopic asthmatics. *Am. J. Respir. Crit. Care Med.* (1999) 160 1947–1951.
- Gopaul N.K., Anggard E.E., Mallet A.I., Betteridge D.J., Wolff S.P., Nourroz-Zadeh J. Plasma 8-epi-PGF<sub>2α</sub> levels are elevated in individuals with non-insulin dependent diabetes mellitus. *FEBS Lett.* (1995) 368 225–229.
- Reilly M., Delanty N., Lawson J.A., Fitzgerald G.A. Modulation of oxidant stress in vivo in chronic cigarette smokers. *Circulation* (1996) 94 19–25.
- McAdam B.F., Mardini I.A., Habib A. et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. *J. Clin. Invest.* (2000) 105 1473–1482.
- Bachi A., Brambilla R., Panelli R., Bianchi R., Zuccato E., Chiabrando C. Reduction of urinary 8-epi-prostaglandin F<sub>2α</sub> during cyclo-oxygenase inhibition in rats but not in man. *Br. J. Pharmacol.* (1997) 121 1770–1774.
- Roberts L.J., Morrow J.D. Measurement of F<sub>2</sub>-isoprostanes as an index of oxidative stress in vivo. *Free Radic. Biol. Med.* (2000) 28 505–513.
- Tsikas D. Application of gas chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry to assess in vivo synthesis of prostaglandins, thromboxane, leukotrienes, isoprostanes and related compounds in humans. *J. Chromatogr. B Biomed. Sci. Appl.* (1998) 717 201–245.
- Berdeaux O., Scrue O., Cracowski J.L., Durand T. F<sub>2</sub>-isoprostanes: review of analytical methods. *Curr. Pharm. Anal.* (2006) 2 69–78.
- Wang Z., Ciabattini G., Crémion C. et al. Immunological characterization of urinary 8-epi-prostaglandin F<sub>2α</sub> excretion in man. *J. Pharmacol. Exp. Ther.* (1995) 275 94–100.
- Cracowski J.L., Devillier P., Durand T., Stanke-Labesque F., Bessard G. Vascular biology of the isoprostanes. *J. Vasc. Res.* (2001) 38 93–103.
- Jaussen L.J. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. *Am. J. Physiol. Lung Cell. Mol. Physiol.* (2001) 280 L1067–L1082.
- Miggin S.M., Kinsella B.T. Thromboxane A<sub>2</sub> receptor mediated activation of the mitogen activated protein kinase cascades in human uterine smooth muscle cells. *Biochim. Biophys. Acta* (2001) 1539 147–162.
- Kinsella B.T. Thromboxane A<sub>2</sub> signalling in humans: a 'Tail' of two receptors. *Biochem. Soc. Trans.* (2001) 29 641–654.
- Daray F.M., Minvielle A.L., Puppo S., Rothlin R.P. Vasoconstrictor effects of 8-iso-prostaglandin E<sub>2</sub> and 8-iso-prostaglandin F<sub>2α</sub> on human umbilical vein. *Eur. J. Pharmacol.* (2004) 499 189–195.
- Fukunaga M., Yura T., Grygorczyk R., Badr K.F. Evidence for the distinct nature of F<sub>2</sub>-isoprostane receptors from those of thromboxane A<sub>2</sub>. *Am. J. Physiol.* (1997) 272 F477–F483.
- McNamara P., Lawson J.A., Rokach J., Fitzgerald G.A. Isoprostane activation of the nuclear hormone receptor PPAR. *Adv. Exp. Med. Biol.* (2002) 507 351–355.
- Pratico D., Smyth E.M., Violi F., Fitzgerald G.A. Local amplification of platelet function by 8-epi prostaglandin F<sub>2α</sub> is not mediated by thromboxane receptor isoforms. *J. Biol. Chem.* (1996) 271 14916–14924.
- Cranshaw J.H., Evans T.W., Mitchell J.A. Characterization of the effects of isoprostanes on platelet aggregation in human whole blood. *Br. J. Pharmacol.* (2001) 132 1699–1706.

- 30 Cambria-Kiely J.A., Gandhi P.J. Possible mechanisms of aspirin resistance. *J. Thromb. Thrombolysis* (2002) 13 49–56.
- 31 Maree A.O., Fitzgerald D.J. Aspirin and coronary artery disease. *Thromb. Haemost.* (2004) 92 1175–1181.
- 32 Martin C.P., Talbert R.L. Aspirin resistance: an evaluation of current evidence and measurement methods. *Pharmacotherapy* (2005) 25 942–953.
- 33 Patrignani P. Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. *Thromb. Res.* (2003) 110 281–286.
- 34 Waugh R.J., Morrow J.D., Roberts L.J., II, Murphy R.C. Identification and relative quantitation of F<sub>2</sub>-isoprostane regioisomers formed in vivo in the rat. *Free Radic. Biol. Med.* (1997) 23 943–954.
- 35 Lawson J.A., Li H., Rokach J. et al. Identification of two major F<sub>2</sub> isoprostanes, 8,12-iso- and 5-epi-8, 12-iso-isoprostane F<sub>2a</sub>-VI, in human urine. *J. Biol. Chem.* (1998) 273 29295–29301.
- 36 Marliere S., Cracowski J.L., Durand T. et al. The 5-series F(2)-isoprostanes possess no vasomotor effects in the rat thoracic aorta, the human internal mammary artery and the human saphenous vein. *Br. J. Pharmacol.* (2002) 135 1276–1280.
- 37 Huber J., Bochkov V.N., Binder B.R., Leitinger N. The isoprostane 8-iso-PGE(2) stimulates endothelial cells to bind monocytes via cyclic AMP- and p38 MAP kinase-dependent signaling pathways. *Antioxid. Redox Signal.* (2003) 5 163–169.
- 38 Leitinger N., Huber J., Rizza C. et al. The isoprostane 8-iso-PGF<sub>2a</sub> stimulates endothelial cells to bind monocytes: differences from thromboxane-mediated endothelial activation. *FASEB J.* (2001) 15 1254–1256.
- 39 Fontana L., Giagulli C., Minuz P., Lechi A., Laudanna C. 8-iso-PGF<sub>2a</sub> induces beta 2-integrin-mediated rapid adhesion of human polymorphonuclear neutrophils: a link between oxidative stress and ischemia/reperfusion injury. *Arterioscler. Thromb. Vasc. Biol.* (2001) 21 55–60.
- 40 Brault S., Martinez-Bermudez A.K., Marrache A.M. et al. Selective neuromicrovascular endothelial cell death by 8-isoprostaglandin F<sub>2alpha</sub>: possible role in ischemic brain injury. *Stroke* (2003) 34 776–782.
- 41 Janssen L.J., Tazzeo T. Involvement of TP and EP3 receptors in vasoconstrictor responses to isoprostanes in pulmonary vasculature. *J. Pharmacol. Exp. Ther.* (2002) 301 1060–1066.
- 42 Cracowski J.L., Devillier P., Chavanon O., Sietchiping-Nzepa F.A., Stanke-Labesque F., Bessard G. Isoprostaglandin E<sub>2</sub> type III (8-iso-prostaglandin E<sub>2</sub>) evoked contractions in human internal mammary artery. *Life Sci.* (2001) 68 2405–2413.
- 43 Catali A., Zhang D., Janssen L.J. Receptors and signaling pathway underlying relaxations to isoprostanes in canine and porcine airway smooth muscle. *Am. J. Physiol. Lung Cell. Mol. Physiol.* (2002) 283 L1151–L1159.
- 44 Morrow J.D., Awad J.A., Wu A., Zacker W.E., Daniel V.C., Roberts L.J., II. Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) in vivo. *J. Biol. Chem.* (1996) 271 23185–23190.
- 45 Chiabrando C., Valagussa A., Rivalta C. et al. Identification and measurement of endogenous beta-oxidation metabolites of 8-epi-prostaglandin F<sub>2a</sub>. *J. Biol. Chem.* (1999) 274 1313–1319.
- 46 Roberts L.J., II, Moore K.P., Zachert W.E., Oates J.A., Morrow J.D. Identification of the major urinary metabolite of the F<sub>2</sub>-isoprostane 8-iso-prostaglandin F<sub>2a</sub> in humans. *J. Biol. Chem.* (1996) 271 20617–20620.
- 47 Basu S. Radioimmunoassay of 8-iso-prostaglandin F<sub>2a</sub>: an index for oxidative injury via free radical catalysed peroxidation. *Prostaglandins Leukot. Essent. Fatty Acids* (1998) 58 319–325.
- 48 Hou X., Roberts L.J., II, Taber D.F. et al. 2,3-Dinor-5,6-dihydro-15-F<sub>2a</sub>-isoprostane: a bioactive prostanoid metabolite. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* (2001) 281 R391–R400.
- 49 Cracowski J.L., Camus L., Durand T. et al. Response of rat thoracic aorta to F<sub>2</sub>-isoprostane metabolites. *J. Cardiovasc. Pharmacol.* (2002) 39 396–403.
- 50 Nourooz-Zadeh J., Halliwell B., Anggard E.E. Evidence for the formation of F<sub>3</sub>-isoprostanes during peroxidation of eicosapentaenoic acid. *Biochem. Biophys. Res. Commun.* (1997) 236 467–472.
- 51 Nourooz-Zadeh J., Liu E.H., Anggard E., Halliwell B. F<sub>4</sub>-isoprostanes: a novel class of prostanoids formed during peroxidation of docosahexaenoic acid (DHA). *Biochem. Biophys. Res. Commun.* (1998) 242 338–344.
- 52 Roberts L.J., II, Montine T.J., Markesbery W.R. et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. *J. Biol. Chem.* (1998) 273 13605–13612.
- 53 Obwegeser R., Oguogho A., Ulm M., Berghammer P., Sinzinger H. Maternal cigarette smoking increases F<sub>2</sub>-isoprostanes and reduces prostacyclin and nitric oxide in umbilical vessels. *Prostaglandins Other Lipid Mediat.* (1999) 57 269–279.
- 54 Morrow J.D., Frei B., Longmire A.W. et al. Increase in circulating products of lipid peroxidation (F<sub>2</sub>-isoprostanes) in smokers. *N. Engl. J. Med.* (1995) 332 1198–1203.
- 55 Oguogho A., Lupattelli G., Palumbo B., Sinzinger H. Isoprostanes quickly normalize after quitting cigarette smoking in healthy adults. *Vasa* (2000) 29 103–105.
- 56 Montuschi P., Collins J.V., Ciabattoni G. et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. *Am. J. Respir. Crit. Care Med.* (2000) 162 1175–1177.
- 57 Chehne F., Oguogho A., Lupattelli G., Budinsky A.C., Palumbo B., Sinzinger H. Increase of isoprostane 8-epi-PGF<sub>2a</sub> after restarting smoking. *Prostaglandins Leukot. Essent. Fatty Acids* (2001) 64 307–310.
- 58 Ahmadzadehfar H., Oguogho A., Efthimiou Y., Kritiz H., Sinzinger H. Passive cigarette smoking increases isoprostane formation. *Life Sci.* (2006) 78 894–897.
- 59 Schwedhelm E., Bartling A., Lenzen H. et al. Urinary 8-iso-prostaglandin F<sub>2alpha</sub> as a risk marker in patients with coronary heart disease: a matched case-control study. *Circulation* (2004) 109 843–848.
- 60 Gross M., Steffes M., Jacobs D.R., Jr et al. Plasma F<sub>2</sub>-isoprostanes and coronary artery calcification: the CARDIA Study. *Clin. Chem.* (2005) 51 125–131.

- 61 Greaves K., Dixon S.R., Coker I.O. et al. Influence of isoprostane F2alpha-III on reflow after myocardial infarction. *Eur. Heart J.* (2004) 25 847–853.
- 62 Iuliano L., Pratico D., Greco C. et al. Angioplasty increases coronary sinus F<sub>2</sub>-isoprostane formation: evidence for in vivo oxidative stress during PTCA. *J. Am. Coll. Cardiol.* (2001) 37 76–80.
- 63 Kromer B., Tippins J.R. Coronary artery constriction by the isoprostane 8-epi-prostaglandin F<sub>2α</sub>. *Br. J. Pharmacol.* (1996) 119 1276–1280.
- 64 Cayatte A.J., Du Y., Oliver-Krasinski J., Lavielle G., Verbeuren T.J., Cohen R.A. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* (2000) 20 1724–1728.
- 65 Pratico D., Tangirala R.K., Rader D.J., Rokach J., FitzGerald G.A. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. *Nat. Med.* (1998) 4 1189–1192.
- 66 Jankov R.P., Belcastro R., Ovcina E. et al. Thromboxane A(2) receptors mediate pulmonary hypertension in 60% oxygen-exposed newborn rats by a cyclooxygenase-independent mechanism. *Am. J. Respir. Crit. Care Med.* (2002) 166 208–214.
- 67 Belhassen L., Pelle G., Dubois-Randé J.L., Adnot S. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. *J. Am. Coll. Cardiol.* (2003) 41 1198–1204.
- 68 Pratico D., Cheng Y., FitzGerald G.A. TP or not TP: primary mediators in a close runoff? *Arterioscler. Thromb. Vasc. Biol.* (2000) 20 1695–1698.
- 69 Ciabattini G., Davi G., Collura M. et al. In vivo lipid peroxidation and platelet activation in cystic fibrosis. *Am. J. Respir. Crit. Care Med.* (2000) 162 1195–1201.
- 70 Davi G., Di Minno G., Coppola A. et al. Oxidative stress and platelet activation in homozygous homocystinuria. *Circulation* (2001) 104 1124–1128.
- 71 Cracowski J.L., Girolet S., Imbert B. et al. Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement. *Free Radic. Biol. Med.* (2005) 38 98–103.
- 72 Patrignani P., Panara M.R., Tacconelli S. et al. Effects of vitamin E supplementation on F<sub>2</sub>-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. *Circulation* (2000) 102 539–545.
- 73 Meagher E.A., Barry O.P., Lawson J.A., Rokach J., FitzGerald G.A. Effects of vitamin E on lipid peroxidation in healthy persons. *JAMA* (2001) 285 1178–1182.
- 74 Weinberg R.B., Vander Werken B.S., Anderson R.A., Stegner J.E., Thomas M.J. Pro-oxidant effect of vitamin E in cigarette smokers consuming a high polyunsaturated fat diet. *Arterioscler. Thromb. Vasc. Biol.* (2001) 21 1029–1033.
- 75 Chowienzyk P.J., Brett S.E., Gopaul N.K. et al. Oral treatment with an antioxidant (roxofelast) reduces oxidative stress and improves endothelial function in men with type II diabetes. *Diabetologia* (2000) 43 974–977.
- 76 Polidori M.C., Pratico D., Ingegneri T. et al. Effects of vitamin C and aspirin in ischemic stroke-related lipid peroxidation: results of the AVASAS (Aspirin Versus Ascorbic acid plus Aspirin in Stroke) Study. *Biofactors* (2005) 24 265–274.
- 77 Meagher E.A., Barry O.P., Burke A. et al. Alcohol-induced generation of lipid peroxidation products in humans. *J. Clin. Invest.* (1999) 104 805–813.
- 78 Levine M., Wang Y., Padayatty S.J., Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. *Proc. Natl. Acad. Sci. U. S. A.* (2001) 98 9842–9846.
- 79 Bruno R.S., Leonard S.W., Atkinson J. et al. Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation. *Free Radic. Biol. Med.* (2006) 40 689–697.
- 80 Higdon J.V., Liu J., Du S.H., Morrow J.D., Ames B.N., Wander R.C. Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde and F<sub>2</sub>-isoprostanes. *Am. J. Clin. Nutr.* (2000) 72 714–722.
- 81 Mori T.A., Dunstan D.W., Burke V. et al. Effect of dietary fish and exercise training on urinary F<sub>2</sub>-isoprostane excretion in non-insulin-dependent diabetic patients. *Metabolism* (1999) 48 1402–1408.
- 82 Visioli F., Caruso D., Galli C., Viappiani S., Galli G., Sala A. Olive oils rich in natural catecholic phenols decrease isoprostane excretion in humans. *Biochem. Biophys. Res. Commun.* (2000) 278 797–799.
- 83 Wiseman H., O'Reilly J.D., Adlercreutz H. et al. Isoflavone phytoestrogens consumed in soy decrease F<sub>2</sub>-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. *Am. J. Clin. Nutr.* (2000) 72 395–400.
- 84 Sanchez-Moreno C., Cano M.P., de Ancos B. et al. Mediterranean vegetable soup consumption increases plasma vitamin C and decreases F(2)-isoprostanes, prostaglandin E(2) and monocyte chemotactic protein-1 in healthy humans. *J. Nutr. Biochem.* (2006) 17 183–189.
- 85 Wiswedel I., Hirsch D., Kropf S. et al. Flavanol-rich cocoa drink lowers plasma F(2)-isoprostane concentrations in humans. *Free Radic. Biol. Med.* (2004) 37 411–421.
- 86 Mitruz P., Patrignani P., Gaiuso S. et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. *Circulation* (2002) 106 2800–2805.
- 87 Cracowski J.L., Baguet J.P., Ormezzano O. et al. Lipid peroxidation is not increased in patients with untreated mild-to-moderate hypertension. *Hypertension* (2003) 41 286–288.
- 88 Ward N.C., Hodgson J.M., Puddey I.B., Mori T.A., Beilin L.J., Croft K.D. Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, and lifestyle. *Free Radic. Biol. Med.* (2004) 36 226–232.



- 89 Mallat Z., Philip I., Lebrete M., Chatel D., Maclouf J., Tedgui A. Elevated levels of 8-iso-prostaglandin  $F_{2a}$  in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. *Circulation* (1998) 97 1536–1539.
- 90 Li H., Lawson J.A., Reilly M. et al. Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine. *Proc. Natl. Acad. Sci. U. S. A.* (1999) 96 13381–13386.
- 91 Cracowski J.L., Tremel F., Marpeau C. et al. Increased formation of F<sub>2</sub>-isoprostanes in patients with severe heart failure. *Heart* (2000) 84 439–440.
- 92 Nonaka-Sarukawa M., Yamamoto K., Aoki H. et al. Increased urinary isoprostane excretion in patients with non-ischemic congestive heart failure: a marker of oxidative stress. *Heart* (2003) 89 871–874.
- 93 Gniwotia C., Morrow J.D., Roberts L.J., Kühn H. Prostaglandin F<sub>2</sub>-like compounds, F<sub>2</sub>-isoprostanes, are present in increased amounts in atherosclerotic lesions. *Arterioscler. Thromb. Vasc. Biol.* (1997) 17 3236–3241.
- 94 Pratico D., Iuliano L., Mauricillo A. et al. Localization of distinct F<sub>2</sub>-isoprostanes in human atherosclerotic lesions. *J. Clin. Invest.* (1997) 100 2028–2034.
- 95 Mehrabi M.R., Ekmekcioglu C., Tatzber F. et al. The isoprostane, 8-epi-PGF<sub>2a</sub>, is accumulated in coronary arteries isolated from patients with coronary heart disease. *Cardiovasc. Res.* (1999) 43 492–499.
- 96 Lindsay T.F., Luo X.P., Lehotay D.C. et al. Ruptured abdominal aortic aneurysm, a 'two-hit' ischemia/reperfusion injury: evidence from an analysis of oxidative products. *J. Vasc. Surg.* (1999) 30 219–228.
- 97 Delanty N., Reilly M.P., Pratico D. et al. 8-epi PGF<sub>2a</sub> generation during coronary reperfusion. *Circulation* (1997) 95 2492–2499.
- 98 Cipollone F., Ciabattini G., Patrignani P. et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. *Circulation* (2000) 102 1007–1013.
- 99 Reilly M.P., Delanty N., Roy L. et al. Increased formation of the isoprostanes IPF<sub>2a</sub>-I and 8-epi-prostaglandin F<sub>2a</sub> in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. *Circulation* (1997) 96 3314–3320.
- 100 Stein C.M., Tanner S.B., Awad J.A., Roberts L.J., Morrow J.D. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. *Arthritis Rheum.* (1996) 39 1146–1150.
- 101 Cracowski J.L., Carpentier P.H., Imbert B. et al. Increased urinary F<sub>2</sub>-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure. *Arthritis Rheum.* (2002) 46 1319–1323.
- 102 Cracowski J.L., Marpeau C., Carpentier P.H. et al. Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. *Arthritis Rheum.* (2001) 44 1143–1148.
- 103 Volpe A., Biasi D., Caramaschi P. et al. Levels of F<sub>2</sub>-isoprostanes in systemic sclerosis: correlation with clinical features. *Rheumatology (Oxford)* (2005) 45 314–320.
- 104 Cracowski J.L., Kom G.D., Salvat-Melis M. et al. Post occlusive reactive hyperemia inversely correlates to urinary 15-F<sub>2t</sub>-isoprostane levels in systemic sclerosis. *Free Radic. Biol. Med.* (2006) 40 1732–1737.
- 105 Pratico D., Ferro D., Iuliano L. et al. Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. *Blood* (1999) 93 3401–3407.
- 106 Martinuzzo M.E., Forastiero R.R., Kordich L., Carreras L.O. Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies. *Br. J. Haematol.* (2001) 114 845–851.
- 107 Cracowski J.L., Cracowski C., Bessard G. et al. Increased lipid peroxidation in patients with pulmonary hypertension. *Am. J. Respir. Crit. Care Med.* (2001) 164 1038–1042.
- 108 Van Kooten F., Ciabattini G., Patrono C., Dipple D.W., Koudstaal P.J. Platelet activation and lipid peroxidation in patients with acute ischemic stroke. *Stroke* (1997) 28 1557–1563.
- 109 Helmersson J., Mattsson P., Basu S. Prostaglandin F<sub>2a</sub> metabolite and F<sub>2</sub>-isoprostane excretion in migraine. *Clin. Sci.* (2002) 102 39–43.
- 110 Regan C.L., Levine R.J., Baird D.D. et al. No evidence for lipid peroxidation in severe preeclampsia. *Am. J. Obstet. Gynecol.* (2001) 185 572–578.
- 111 Walsh S.W., Vaughan J.E., Wang Y., Roberts L.J., II Placental isoprostane is significantly increased in preeclampsia. *FASEB J.* (2000) 14 1289–1296.
- 112 Morris J.M., Gopaul N.K., Endresen M.J. et al. Circulating markers of oxidative stress are raised in normal pregnancy and pre-eclampsia. *Br. J. Obstet. Gynaecol.* (1998) 105 1195–1199.
- 113 Barden A., Beilin L.J., Ritchie J., Croft K.D., Walters B.N., Michael C.A. Plasma and urinary 8-iso-prostane as an indicator of lipid peroxidation in pre-eclampsia and normal pregnancy. *Clin. Sci. (Colch)* (1996) 91 711–718.
- 114 McKinney E.T., Shouri R., Hunt R.S., Ahokas R.A., Sibai B.M. Plasma, urinary, and salivary 8-epi-prostaglandin F<sub>2a</sub> levels in normotensive and preeclamptic pregnancies. *Am. J. Obstet. Gynecol.* (2000) 183 874–877.
- 115 Parra M., Rodrigo R., Barja P. et al. Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. *Am. J. Obstet. Gynecol.* (2005) 193 1486–1491.
- 116 Harsen N.K., Braekke K., Staff A.C. Augmented oxidative stress as well as antioxidant capacity in maternal circulation in preeclampsia. *Eur. J. Obstet. Gynecol. Reprod. Biol.* (2005) [Epub ahead of print].

Q  
TAR 927

bru

American Heart  
Association®



Learn and Live<sup>SM</sup>


# Arteriosclerosis, Thrombosis, and Vascular Biology

EBLING LIBRARY  
UNIVERSITY OF WISCONSIN

FEB 09 2006

750 Highland Avenue  
Madison, WI 53705

JOURNAL OF THE AMERICAN HEART ASSOCIATION



Smoking and metalloproteinases.  
*Arterioscler Thromb Vasc Biol.* 2006;26:250-256.

## ■ Editorials

Adiponectin: Vascular Protection From the Fat?  
Arginine/Arginase NO NO NO  
AT1 Receptors, Venules, and Hypercholesterolemia

## ■ Brief Reviews

Diet and Murine Atherosclerosis  
Smoking, Metalloproteinases, and Vascular Disease

Risk Factors and Endothelial Progenitor Cells  
eNOS: Host Defense Enzyme of the Endothelium?

## ■ Vascular Biology

JAM-A and Neointimal Hyperplasia  
Aspirin, Inflammation, and Gender  
TNF- $\alpha$ , JNK, and Insulin-Mediated Vasoreactivity  
Vascular Progenitor Cells in Adult Normal Arteries  
Radiation Induced Microvascular Gut Endothelium Dysfunction  
IL-18 and MIF in Development of Intima-Media Thickening  
FGFR4 Regulates PON1 mRNA and Plasma HDL  
Conjugated Linoleic Acid and Endothelial Function  
AT1 and Hypercholesterolemia

## ■ Atherosclerosis and Lipoproteins

Expression Profiling of Atherosclerotic Plaque  
Myofibroblasts in Human Coronary Plaques  
Nox Expression in Human Coronary Artery Disease  
MMP-9 and Plaque Stability  
Neovascularization in Aortas of ApoE<sup>-/-</sup>/LDL<sup>-/-</sup> Mice  
T-Cell Dynamic in Atherogenesis  
Apolipoprotein Deposits in Atherosclerosis  
Macrophage Arginase in Atherosclerosis Resistance  
Increasing Cholesterol Affects Macrophage Behavior  
Renal and Vascular Function  
ApoA-I Kinetics in HRT  
A Gene for HDL-C Resides on Chromosome 4q31.21  
Endothelial Dysfunction and Type 2 Diabetes  
ApoB/AI Ratio and the Metabolic Syndrome  
Socioeconomic Factors and IMT Progression

## ■ Thrombosis

Impaired Insulin Signaling in DM2 Platelets  
Measuring TAFI Activation

## ■ Letters to the Editor

Quantification of Abdominal Aortic Calcification on CT  
Insulin Resistance and Increased IMT in T2DM  
Salivary Lysozyme and Prevalent Coronary Heart Disease  
Homeostatic Risk Factors and Arterial Thrombotic Events  
CD8<sup>+</sup> T Cell Subpopulations in AAA Lesion and Response  
Vitamin E Limits AAA  
Leukocytosis, Vascular Disease, and Adenine Nucleotide Metabolism

# Arteriosclerosis, Thrombosis, and Vascular Biology

Volume 26 Number 2 February 2006



This article contains online supplementary information that is available at <http://www.atvbaha.org>.

## Brief Reviews

### Diet and Murine Atherosclerosis

Godfrey S. Getz, Catherine A. Reardon ..... 242

Murine models of atherosclerosis have been fed a variety of diets that vary in the level of cholesterol, the level and type of fatty acid, and the absence and presence of cholate. This review summarizes what is known about the effect of these dietary components on lipoprotein levels and/or atherosclerosis.

### Smoking, Metalloproteinases, and Vascular Disease

Todd S. Perlstein, Richard T. Lee ..... 250

The matrix metalloproteinases are emerging as strong candidate mediators of smoking-associated vascular disease. Smoking-induced inflammation and oxidative stress may increase metalloproteinase transcription, increase pro-enzyme activation, and limit endogenous inhibition of metalloproteinase activity. The relationship between smoking, metalloproteinases, and vascular disease is discussed in this brief review.

### Influence of Cardiovascular Risk Factors on Endothelial Progenitor Cells: Limitations for Therapy?—ATVB In Focus

Nikos Werner, Georg Nickenig ..... 257

Circulating endothelial progenitor cells play an important role in restoration of the endothelium after endothelial cell damage. The current review focuses on the role of cardiovascular risk factors on endothelial cell apoptosis and progenitor cell-mediated vasculoprotection.

### Endothelial NO Synthase: Host Defense Enzyme of the Endothelium?

Ton J. Rabelink, Thomas F. Luscher ..... 267

This article explores the physiology of superoxide generation by endothelial nitric oxide synthase, the so-called "uncoupled" state of the enzyme. The fact that this alternative chemistry of the eNOS enzyme is evolutionary strongly conserved, suggests that it may play a physiological role. It is proposed that this uncoupled state may contribute to defense against infections, and the central role of uncoupled eNOS in redox signaling in the endothelium may open up new avenues for therapy to prevent atherosclerosis.

## Vascular Biology

### Importance of Junctional Adhesion Molecule-A for Neointimal Lesion Formation and Infiltration in Atherosclerosis-Prone Mice

Alma Zernecke, Elisa A. Liehn ... Christian Weber [Web Site Feature] ..... e10–e13

Abstract ..... 272

Junctional adhesion molecule-A (JAM-A) has recently been implicated in leukocyte recruitment on early atherosclerotic endothelium. Our data provide the first evidence to our knowledge for a crucial role of JAM-A in accelerated lesion formation and monocyte infiltration in atherosclerosis-prone mice.

### Aspirin Has A Gender-Dependent Impact on Antiinflammatory 15-Epi-Lipoxin A<sub>4</sub> Formation: A Randomized Human Trial

Nan Chiang, Shelley Hurwitz ... Charles N. Serhan [Web Site Feature] ..... e14–e17

Abstract ..... 273

In a double-blinded clinical trial, low-dose aspirin significantly increased the antiinflammatory mediator, aspirin-triggered-15-epi-lipoxinA<sub>4</sub>. A post-trial analysis showed that the age trends in aspirin-triggered-15-epi-lipoxinA<sub>4</sub> formation are significantly different with genders: a positive correlation in women and a negative correlation in men. Therefore, aspirin-triggered-15-epi-lipoxinA<sub>4</sub> may be related to the gender-specific clinical impact of aspirin.

ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY (ISSN 1079-5642) is published monthly by Lippincott Williams & Wilkins, at 16522 Hunters Green Parkway, Hagerstown, MD 21740. Business offices are located at 530 Walnut Street, Philadelphia, PA 19106-3621. Production offices are located at 351 West Camden Street, Baltimore, MD 21201-2436. For institutional rates in Japan, contact Igaku-Shoin MYW, Ltd., 3-23-14 Hongo, Bunkyo-ku, Tokyo 113, Japan. Individuals may subscribe for their personal use at the following annual rates: \$217 for members of an American Heart Association scientific council and \$355 for nonmembers; international: \$266 for members of an American Heart Association scientific council and \$419 for nonmembers. Periodicals postage paid at Hagerstown, MD and additional mailing offices. POSTMASTER: Send address changes to ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, American Heart Association, Lippincott Williams & Wilkins, 12107 Insurance Way, Hagerstown, MD 21740.

# Conjugated Linoleic Acid Impairs Endothelial Function

Justin S.W. Taylor, Simon R.P. Williams, Rhian Rhys, Phillip James, Michael P. Frenneaux

**Objectives**—To determine the effect of dietary supplementation with conjugated linoleic acid (CLA) on body mass index (BMI), body fat distribution, endothelial function, and markers of cardiovascular risk.

**Methods and Results**—Forty healthy volunteers with BMI >27 kg/m<sup>2</sup> were randomized to receive a CLA isomeric mixture or olive oil in a 12-week double-blind study. Subcutaneous body fat and abdominal/hepatic fat content were assessed using skin-fold thicknesses and computed tomography scanning, respectively. Endothelial function was assessed by brachial artery flow-mediated dilatation (FMD). Plasma isoprostanes were measured as an index of oxidative stress. CLA supplementation did not result in a significant change in BMI index or total body fat. There was a significant decrease in limb (−7.8 mm,  $P<0.001$ ), but not torso skin-fold thicknesses or abdominal or liver fat content. Brachial artery FMD declined (−1.3%,  $P=0.013$ ), and plasma F2-isoprostanes increased (+91pg/mL,  $P=0.042$ ).

**Conclusions**—A CLA isomeric mixture had at most modest effects on adiposity and worsened endothelial function. On the basis of these results, the use of the isomeric mixture of CLA as an aid to weight loss cannot be recommended. (*Arterioscler Thromb Vasc Biol.* 2006;26:307-312.)

**Key Words:** body composition ■ conjugated linoleic acid ■ endothelial function ■ obesity ■ oxidative stress

Abdominal obesity<sup>1</sup> and the associated dysmetabolic syndrome<sup>2</sup> confer increased cardiovascular risk. Dietary modification with n-3 polyunsaturated fatty acids appears to reduce the risk of coronary artery disease and improve mortality.<sup>3-5</sup> Conjugated linoleic acid (CLA) is a naturally occurring fatty acid and is found in dairy products and meat from ruminants. It differs from the better known linoleic acid by having an extra carbon-carbon double bond. It has been widely promoted in the lay press,<sup>6</sup> with claims that it can prevent and treat cancer,<sup>7</sup> prevent heart disease,<sup>8</sup> improve immune function,<sup>9</sup> and treat obesity.<sup>10</sup> Whereas some of these effects are supported by studies in animals,<sup>8,11</sup> there is conflicting published human research on CLA, and in particular there have been no conclusive studies measuring its effect on markers of cardiovascular risk. Furthermore, it is now realized that the different isomers of CLA may have very different biological properties and may have different mechanisms of action.<sup>12</sup> The 2 main CLA isomers that have been studied are 9,11 and 10,12 CLA. Other studies have suggested that CLA supplementation may increase oxidative stress, although this was not proven.<sup>16,17</sup> Furthermore, the small number of studies thus far published have suggested that in humans, weight loss produced by CLA supplementation is at most modest.<sup>10,13,16,18</sup> To assess the efficacy of CLA as an aid to weight loss and its effect on cardiovascular risk factors, we undertook a double blind study examining the effects of a commercially available isomeric mixture of CLA on body weight, body fat mass and distribution, endothelial

function, insulin sensitivity, and markers of oxidative stress in overweight middle-aged men.

## Methods

### Subjects

Forty nonsmoking white men, aged 35 to 60, without diabetes, hypertension, or cardiovascular disease, with a body mass index (BMI) >27 kg/m<sup>2</sup> were recruited from the local community through media advertisements. All subjects gave informed written consent and the protocol was approved by the local research and ethics committee.

### Protocol

Subjects were randomly assigned to receive 4.5 g/d of CLA (isomeric mixture 60 calories/d) or olive oil (54 calories/d). The randomization was performed by an independent observer who also matched subjects by age and BMI. The isomeric mixture contained 35% 9c,11t CLA, 36% t10,c12 CLA, 1% to 2% 9c,11c and 10c,12c CLA, 1.5% 9t,11t and 10t,11t CLA, and <1% t8,c10 and c11,t13 CLA. The CLA and olive oil capsules were supplied by Natural Lipids (Hovdebygd, Norway). All vascular measurements were made in the morning after an overnight fast, at the beginning of the study, and after 12 weeks of supplementation.

### Body Composition

Body weight and height were measured and BMI calculated. Skin-fold thicknesses were measured according to standard guidelines<sup>19</sup> with Harpenden skinfold calipers (Holtain Ltd, Crymch, UK) at the following sites: biceps, triceps, front mid-thigh, medial calf, subscapular, mid-axillary, and abdominal. Abdominal, waist, and hip girths were measured. All measurements were made in triplicate and averaged. Bioelectrical impedance analysis was performed using the

Original received January 24, 2005; final version accepted November 29, 2005.

From Morriston Hospital, Swansea, UK; University of Glamorgan, Pontypridd, UK; Royal Glamorgan Hospital, Llantrisant, UK; Wales Heart Research Institute, Cardiff, UK; Dept Cardiovascular Medicine, The University of Birmingham, Birmingham, UK.

Source of funding: British Heart Foundation Project Grant.

Correspondence to Justin S. W. Taylor, Department of Cardiology, Morriston Hospital, Morriston, Swansea SA6 6NL, UK. E-mail jswt@totalise.co.uk  
© 2006 American Heart Association, Inc.

*Arterioscler Thromb Vasc Biol.* is available at <http://www.atvbaha.org>

DOI: 10.1161/01.ATV.0000199679.40501.ac

tetrapolar method and a Bodystat 1500 analyser (Bodystat Ltd, Isle of Man). Abdominal adipose tissue and liver fat were measured using two computed tomography (CT) images as described previously.<sup>20</sup> Abdominal adipose tissue is presented as a surface area at the level of the fourth lumbar vertebrae, and hepatic and splenic fat is presented as radiographic density in Hounsfield units (HU). Images were acquired using a Somatom Plus 4 scanner. CT slices were 10 mm in thickness and were obtained at 120 kV and 200 mA, with a 42-cm field of view and a 512×512 matrix. Image analysis was performed using dedicated software (SliceOmatic Version 4.2; Tomovision, Montreal, Canada).

### Endothelial Function

Changes in brachial artery diameter in response to reactive hyperemia (FMD) were measured noninvasively using a high-resolution ultrasonic wall-tracking system (Vadirec Wall-track System™) as previously validated.<sup>21,49,50</sup> Studies were performed at a controlled temperature of 21°C, with subjects supine and their arm held outstretched on a cushion. Baseline measurements of internal brachial artery diameter were taken after 15 minutes of rest. Reactive hyperemia was produced by releasing a pediatric sphygmomanometer wrist cuff inflated to systolic pressure plus 50 mm Hg for 5 minutes. Internal brachial artery diameter was measured every minute after cuff release, and the maximum change from baseline was used to calculate FMD. Data are presented as the percentage diameter change from baseline in the brachial artery.

### Laboratory Measurements

Venous blood samples were freshly analyzed for glucose, insulin, cholesterol (including low-density lipoprotein and high-density lipoprotein), and C-reactive protein. Further samples were centrifuged and the supernatant frozen at -80°C. These samples were analyzed later using enzyme immuno-linked assays for leptin (Alexis), adiponectin (Biogenesis UK), F2-isoprostanes (Alexis), and tumor necrosis factor- $\alpha$  (paired antibody enzyme-linked immunosorbent assay). Insulin sensitivity was measured indirectly using HOMA-IR [fasting serum insulin ( $\mu$ U/mL)×fasting plasma glucose (mmol/L)/22.5].

### Statistical Analysis

Analysis was performed using SPSS v11.5. Baseline values are presented as mean±SD. Variables with a skewed distribution were logarithmically transformed to achieve a normal distribution prior to analysis. Baseline comparison between the CLA and olive oil groups was assessed by Student *t* test. The effects of treatment with CLA versus olive oil were assessed by using ANCOVA using baseline values as covariates and are presented with 95% confidence intervals. To avoid type I errors, post-hoc Bonferroni corrections were applied to the groups of primary objective measurements. Therefore, 2-tailed  $P<0.025$ ,  $P<0.005$ ,  $P<0.001$ ,  $P<0.025$ , and  $P<0.008$  were regarded as significant for blood pressure, skin-folds, girths, FMD, and abdominal CT measurements, respectively. A 2-tailed  $P<0.05$  was regarded as significant for primary objective measurements weight, and bioimpedance, and the exploratory blood analyses.

### Results

Baseline measurements did not differ significantly in the olive oil (19 subjects) and CLA (21 subjects) groups (Table 1). All subjects completed the study. The effect of 12 weeks of supplementation is shown in Table 2. The important changes are also displayed in the Figure. There were no significant changes in parameters in the olive oil group except for a decline in tumor necrosis factor- $\alpha$  (-61pg/mL [95% CI, -3 to -120];  $P=0.04$ ). In the CLA group there was no significant change in body mass (-1.1 kg [95% CI, -2.3 to 0.04];  $P=0.06$ ), BMI (-0.4kg/m<sup>2</sup> [95% CI, -0.8 to 0.03];  $P=0.07$ ), or total body fat (-1% [95% CI, -2.5 to 0.5];

**TABLE 1. Characteristics of Olive Oil and CLA Groups at the Start of the Study**

Baseline Characteristic	Olive Oil (n=19)	CLA (n=21)	P
Age, y	47±8	45±6	NS
Mass, kg	97±13	101±9	NS
BMI	33±3	33±3	NS
Fat, % (Bioimpedance)	29±3	28±4	NS
Systolic BP, mm Hg	128±13	122±10	NS
Diastolic BP, mm Hg	85±7	80±8	NS
Anthropometric measurements			
Skin-folds: Biceps, mm	12±4	11±4	NS
Skin-folds: Triceps, mm	20±5	19±5	NS
Skin-folds: Mid-thigh, mm	23±7	25±8	NS
Skin-folds: Medial calf, mm	16±4	16±5	NS
Skin-folds: Subscapular, mm	32±6	32±7	NS
Skin-folds: Mid-axillary, mm	23±4	24±6	NS
Skin-folds: Abdominal, mm	33±7	35±6	NS
Skin-folds: Limb, mm	72±17	72±18	NS
Skin-folds: Torso, mm	123±13	128±16	NS
Skin-folds: Torso:Limb	1.8±0.4	1.9±0.3	NS
Girth: Abdomen, cm	107±7	107±6	NS
Girth: Waist, cm	112±7	112±7	NS
Girth: Hip, cm	110±6	110±5	NS
Girth: Waist:Hip	1.02±0.03	1.01±0.04	NS
Girth: Abdominal:Hip	0.98±0.05	0.97±0.05	NS
Endothelial function			
Brachial artery, mm	3.8±0.5	3.7±0.4	NS
Brachial artery FMD, %	2.1±2.1	2.2±2.7	NS
Abdominal CT measurements			
Liver, HU	60±13	66±10	NS
Spleen, HU	64±2	61±2	NS
Liver:Spleen	0.93±0.18	1.08±0.18	NS
Visceral area, cm <sup>2</sup>	242±82	204±70	NS
Subcutaneous fat area, cm <sup>2</sup>	341±80	357±93	NS
Visceral:Subcutaneous fat	0.75±0.38	0.63±0.37	NS
Blood analyses			
LDL cholesterol, mmol/L	3.6±0.9	3.4±0.8	NS
HDL cholesterol, mmol/L	1.0±0.3	1.1±0.3	NS
Total cholesterol, mmol/L	5.6±0.9	5.4±0.8	NS
Triglycerides, mmol/L	2.3±1.3	1.8±1.0	NS
CRP, mg/L	5.2±2.9	4.8±2.7	NS
Glucose, mmol/L	5.2±0.6	5.1±0.7	NS
Insulin, mU/L	18±22	13±7	NS
HOMA-IR	4.6±6.4	3.1±1.8	NS
Leptin, ng/mL	21±12	22±16	NS
Adiponectin, pg/mL	8±6	9±6	NS
F2-isoprostanes, pg/mL	135±67	99±103	NS
Tumor necrosis factor- $\alpha$ , pg/mL	122±97	109±145	0.04

NS indicates not significant.

$P=0.18$ ). There was a significant decrease in limb (-7.8 mm [95% CI, -11.1 to -4.5];  $P<0.001$ ), but not torso (-4.0 mm [95% CI, -11.5 to 3.5];  $P=0.29$ ) skin folds, and a significant increase in the total torso-to-limb skin-fold ratio(+0.13 [95%


**TABLE 2.** Change in Measurements in Each Treatment Group After 12 Weeks of Supplementation Plus ANCOVA Analyses Showing the Overall Effect of Supplementation With CLA

	Olive Oil	CLA	Change in Measurement (ANCOVA) [95%CI]
Mass, kg	0.9±1.4	-0.2±1.9	-1.1 [-2.3 to 0.04] ( <i>P</i> =0.06)
BMI	0.3±0.5	-0.1±0.7	-0.4 [-0.8 to 0.03] ( <i>P</i> =0.07)
Fat, % (Bioimpedance)	1.1±2.9	0.1±1.7	-1 [-2.5 to 0.5] ( <i>P</i> =0.18)
Systolic BP, mm Hg	0.2±6.7	-0.4±9.1	-2.2 [-7.1 to 2.7] ( <i>P</i> =0.37)
Diastolic BP, mm Hg	-0.8±7.5	0.1±5.7	-1.3 [-5.4 to 2.8] ( <i>P</i> =0.52)
<b>Anthropometric measurements</b>			
Skin-folds: Biceps, mm	0.1±2.3	-1.4±1.5	-1.6 [-2.7 to -0.5] ( <i>P</i> =0.005)
Skin-folds: Triceps, mm	0.3±1.9	-1.1±2.4	-1.5 [-2.9 to 0.03] ( <i>P</i> =0.046)
Skin-folds: Mid-thigh, mm	0.4±2.1	-2.6±2.6	-2.8 [-4.3 to -1.3] ( <i>P</i> <0.001)
Skin-folds: Medial calf, mm	0.2±1.4	-1.5±1.5	-1.8 [-2.7 to -0.8] ( <i>P</i> =0.001)
Skin-folds: Sub-scapular, mm	0.9±3.3	-0.3±4.8	-1.3 [-3.8 to 1.2] ( <i>P</i> =0.29)
Skin-folds: Mid-axillary, mm	-0.4±2.8	-3.0±3.0	-2.3 [-4.0 to -0.6] ( <i>P</i> =0.011)
Skin-folds: Abdominal, mm	2.0±6.8	2.2±3.4	+1.4 [-1.6 to 4.3] ( <i>P</i> =0.36)
Skin-folds: Limb, mm	1.1±3.5	-6.6±6.0	-7.8 [-11.1 to -4.5] ( <i>P</i> <0.001)
Skin-folds: Torso, mm	2.9±13.5	-2.1±9.9	-4.0 [-11.5 to 3.5] ( <i>P</i> =0.29)
Skin-folds: Torso:Limb	0.02±0.18	0.15±0.15	+0.13 [0.03 to 0.24] ( <i>P</i> =0.017)
Girth: Abdomen, cm	0.1±1.3	-0.1±1.9	-0.2 [-1.4 to 0.9] ( <i>P</i> =0.69)
Girths: waist, cm	-0.3±2.1	0.5±2.5	+0.8 [-0.8 to 2.4] ( <i>P</i> =0.30)
Girths: hip, cm	0.4±1.4	-0.01±1.5	-0.4 [-1.3 to 0.6] ( <i>P</i> =0.44)
Girths: Waist:Hip	-0.003±0.03	0.01±0.22	+0.01 [-0.01 to 0.02] ( <i>P</i> =0.44)
Girths: Abdominal:Hip	-0.01±0.03	-0.01±0.01	+0.01 [-0.01 to 0.02] ( <i>P</i> =0.42)
<b>Endothelial function</b>			
Brachial artery, mm	-0.17±0.60	-0.03±0.62	+0.06 [-0.29 to 0.41] ( <i>P</i> =0.72)
Brachial artery FMD, %	0.1±2.3	-1.3±2.5	-1.3 [-2.4 to -0.3] ( <i>P</i> =0.013)
<b>Abdominal CT measurements</b>			
Liver, HU	-0.7±5.7	-4.1±10.2	-3.9 [-9.9 to 2.2] ( <i>P</i> =0.20)
Spleen, HU	-2.2±4.8	0.7±2.8	1.1 [-1.7 to 3.8] ( <i>P</i> =0.44)
Liver:Spleen	0.01±0.11	-0.08±0.17	-0.09 [-0.21 to 0.03] ( <i>P</i> =0.12)
Visceral area, cm <sup>2</sup>	11.1±34.5	3.7±55.0	-4.5 [-33.6 to 24.6] ( <i>P</i> =0.76)
Subcutaneous fat area, cm <sup>2</sup>	-9.8±32.6	3.43±40.0	-12.6 [-39.5 to 14.2] ( <i>P</i> =0.34)
Visceral:Subcutaneous fat	-0.09±0.26	0.03±0.29	0.08 [-0.11 to 0.26] ( <i>P</i> =0.41)
<b>Blood analyses</b>			
LDL cholesterol, mmol/L	-0.2±0.5	-0.01±0.4	+0.1 [-0.1 to 0.3] ( <i>P</i> =0.41)
HDL cholesterol, mmol/L	-0.03±0.11	-0.09±0.13	-0.03 [-0.10 to 0.05] ( <i>P</i> =0.46)
Total cholesterol, mmol/L	-0.09±0.50	-0.07±0.44	-0.07 [-0.34 to 0.20] ( <i>P</i> =0.62)
Triglycerides, mmol/L	0.1±0.8	0.1±0.8	-0.1 [-0.6 to 0.4] ( <i>P</i> =0.57)
CRP, mg/L	-0.8±2.9	0.4±4.8	+0.9 [-1.4 to 3.2] ( <i>P</i> =0.41)
Glucose, mmol/L	0.3±0.8	0.2±0.8	-0.1 [-0.5 to 0.3] ( <i>P</i> =0.51)
Insulin, mU/L	0.7±22.2	2.3±12.6	-3 [-11 to 6] ( <i>P</i> =0.50)
HOMA-IR	0.2±6.7	0.8±3.2	-0.8 [-3.2 to 1.6] ( <i>P</i> =0.50)
Leptin, ng/mL	1.3±7.3	0.7±5.1	-0.7 [-4.8 to 3.4] ( <i>P</i> =0.72)
Adiponectin, pg/mL	0.5±3.4	-0.2±4.0	-0.2 [-2.4 to 2.0] ( <i>P</i> =0.84)
F2-isoprostanes, pg/mL	-36±95	94±200	+91 [3 to 178] ( <i>P</i> =0.042)
Tumor necrosis factor- $\alpha$ , pg/mL	-61±70	15±21	+45 [-11 to 101] ( <i>P</i> =0.11)

CI, 0.03 to 0.24]; *P*=0.017). There was no significant change in abdominal, waist, or hip girths, or in subcutaneous abdominal fat and liver fat measured by CT. However, there was a significant decrease in brachial artery FMD (-1.3% [95% CI,

-2.4 to -0.3]; *P*=0.013), and a significant increase in plasma F2-isoprostanes(+91pg/mL [95% CI, 3 to 178]; *P*=0.042). There was no change in estimated insulin sensitivity, total cholesterol, low-density lipoprotein cholesterol,





Main findings of changes caused by CLA using baseline values as covariates (ANCOVA).

high-density lipoprotein cholesterol, triglycerides, CRP, leptin, or adiponectin.

There was a significant negative correlation between change in F2-isoprostanes and change in total limb skin folds (ie, loss of limb skin-fold thickness was associated with an increase in F2-isoprostanes) for the entire group (CLA+olive oil) ( $P=0.012$ ) but no significant correlation when each group was analyzed separately. There was no significant correlation between change in endothelial function and change in F2-isoprostanes or change in limb skin-fold thicknesses.

### Discussion

Obesity, and in particular abdominal obesity, is associated with increased cardiovascular risk,<sup>22–24</sup> and intentional weight reduction improves cardiovascular risk.<sup>25,26</sup> Recently there has been a great deal of interest in the effect of the Mediterranean diet on cardiovascular risk. A 2-year study examining the effect of the Mediterranean diet in patients with the metabolic syndrome found a reduction in body weight, an improvement in endothelial function, a decrease in CRP and an improvement in insulin resistance.<sup>27</sup> A study that tried to identify which component of the Mediterranean diet was responsible for improving cardiovascular risk paradoxically found that olive oil impaired endothelial function, although this was inversely correlated with changes in triglycerides.<sup>28</sup> The conclusion of the study was that it was the antioxidant and omega-3-rich foods that conferred cardiovascular benefit. Nevertheless, these studies supported the view that dietary modification or supplementation may have a significant impact on obesity and, in particular, cardiovascular risk.

Experimental evidence in animal models suggests that CLA supplementation, in particular the 10,12 CLA isomer, induces fat mass loss.<sup>29–32</sup> On the basis of this initial evidence, there has been a great deal of interest in its use as an aid to lose fat and weight in humans. Blankson et al reported that 12-week supplementation with  $>3.4$  g/d isomeric CLA significantly reduced body fat mass in overweight volunteers, although there was no change in weight or BMI,<sup>10</sup>

and Riserus et al found that only 4-week supplementation with 4.2 g/d isomeric CLA significantly improved sagittal abdominal diameter.<sup>33</sup> However, Zambell et al found no significant change in weight, BMI, or fat mass after 3-g/d supplementation with isomeric CLA (in women who were not overweight).<sup>18</sup> The observation in two studies of an impairment of insulin sensitivity have raised concerns.<sup>13–15</sup> This study was therefore designed to assess the effect of CLA supplementation on BMI, body fat distribution, and markers of cardiovascular risk, including endothelial function.

Our study found that an isomeric mixture of CLA did not cause significant weight loss (although there was a trend to weight loss of 1.1 kg). This is consistent with the 0.24 to 0.46 kg weight loss reported in previous studies.<sup>13,18</sup> Although CLA reduced limb fat, it had no effect on abdominal fat or liver fat (although there was a nonsignificant trend to an increase in liver fat, measured as a decrease in liver density in Hounsfield units). This finding is in contrast to a previous report that found a decrease in sagittal abdominal diameter after 4 weeks of 4.2 g/d CLA.<sup>33</sup> However, the suggestion that CLA may have a lipodystrophic effect is not new. A study supplementing mice with isomeric CLA found a reduction in fat mass, liver hypertrophy, and an increase in insulin resistance,<sup>34</sup> whereas mice fed the 10,12 CLA isomer had hyperinsulinemia and an increase in liver fat develop.<sup>35</sup> The mechanism for this is not clear, although a rapid decrease in leptin and adiponectin has been observed in mice only 2 days after starting CLA supplementation.<sup>36</sup> A decrease in leptin has also been observed in rats.<sup>37</sup> This hypothesis is supported by the observation that hyperinsulinemia and liver steatosis are partially reversed when hypoleptinemia is normalized by leptin infusion in CLA lipoatrophic mice.<sup>34</sup> However, there is conflicting evidence regarding the effects of CLA supplementation on plasma leptin in humans. One study supplementing patients with type 2 diabetes with CLA found a decrease in leptin,<sup>38</sup> but another study supplementing obese men with CLA found no change in leptin.<sup>13</sup> No clinical studies in humans have measured adiponectin after CLA supplementation. In contrast to these findings, a study supplementing Zucker diabetic fatty rats with CLA found that the previous impaired glucose tolerance improved.<sup>39</sup>

Cell culture and animal studies have suggested several other potential mechanisms by which CLA may reduce body fat, including reducing apolipoprotein B secretion in HepG2 cells,<sup>40</sup> increasing carnitine palmitoyltransferase activity and decreasing lipoprotein lipase activity,<sup>30</sup> and increasing tumor necrosis factor and uncoupling protein levels.<sup>34</sup> The role of peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) activity is not clear. PPAR $\gamma$  activity was increased in Zucker diabetic fatty rats and genetically obese mice fed CLA,<sup>39,41,42</sup> although several *in vitro* studies have found that 10,12 CLA downregulates PPAR $\gamma$  activity in mice adipocytes.<sup>43,44</sup> *In vivo* and *in vitro* studies in pigs have also found that CLA induced an increase in PPAR $\gamma$  activity.<sup>45</sup> However, human studies have found an opposite effect on PPAR $\gamma$ . Human adipocytes cultured *in vitro* with 10,12 CLA decreased the expression of PPAR $\gamma$ ,<sup>41,43</sup> and diabetic patients treated with PPAR $\gamma$  agonists (glitazones) experience decreased central fat and increased peripheral fat.<sup>46</sup>

Our observations are important because reducing nonabdominal fat is less likely to reduce cardiovascular risk, and an increase in hepatic fat will increase insulin requirements.<sup>47</sup> Thus any weight loss with this regime is at most modest and the pattern of weight loss is not metabolically favorable.

Furthermore, we found that CLA significantly impaired brachial artery endothelial function, consistent with an adverse impact on cardiovascular risk.<sup>51</sup> The mechanism of this effect is not clear. We and others<sup>16</sup> found an increase in F<sub>2</sub> isoprostanes, a lipid peroxidation product generally considered to be a marker of increased oxidative stress. Another previous study reported an increase in plasma CRP, a marker of inflammation.<sup>17</sup> Taken together, these data suggest that this CLA regime impairs endothelial function and that this may, at least in part, be caused by increased oxidative stress. It is possible that the observed change in FMD in this study has been caused by the change in limb skin-fold thicknesses interfering with the FMD technique (for example, by altering wrist arterial occlusion pressure or changing depth from probe to brachial artery), thus giving a false measurement. However, we feel that this is unlikely because a high wrist arterial occlusion pressure was used and a change in depth to the brachial artery of 1 to 2 mm is well within the capability of the ultrasound probe. Brachial artery FMD measurements vary markedly from laboratory to laboratory, dependant on the exact technique used.<sup>48</sup> In this study, we used the wrist cuff technique, which results in lower values of brachial artery FMD than those obtained using the upper arm or mid-forearm techniques. We did not observe an adverse impact on insulin sensitivity. However, the study may have been under-powered to detect differences using the HOMA technique.<sup>52</sup> We did not identify any change in plasma lipid profiles.

The effect of CLA on other cardiovascular risk factors has been examined. One study reported that CLA decreased platelet aggregability,<sup>53</sup> but another reported no change in platelet aggregability.<sup>54</sup> A small decrease in total, low-density lipoprotein, and high-density lipoprotein cholesterol was found in overweight men taking 1.7 g/d CLA and 3.4 g/d CLA, although this was not maintained at higher doses.<sup>10</sup> A further study in obese men using 10,12 CLA and a CLA mixture lowered high-density lipoprotein cholesterol, although no change was observed in total or low-density lipoprotein cholesterol or triglycerides.<sup>13</sup> No change in lipids was found in a study with healthy women supplemented with 3.9 g/d CLA.<sup>55</sup>

Consistent with our observations, 4.2 g/d CLA for 1 month was found to increase urinary isoprostanes in men with abdominal obesity.<sup>16</sup> Isoprostanes are produced from peroxidation of lipids, and it was suggested that the increase in isoprostanes might be simply a result of increased fat lipolysis, rather than indicating increased oxidative stress. However, more recent studies have found that 10,12 CLA increases insulin resistance<sup>13</sup> and plasma CRP.<sup>17</sup> Taken together with our observation of an impairment of endothelial function, it seems highly likely that the increase in isoprostanes does indeed imply an increase in oxidative stress.

## Conclusions

CLA supplementation for 12 weeks using the regime used in this study had no significant effect on BMI. Even if this represents a type 2 error, the reduction is at most modest, consistent with previous reports in man. Furthermore, the pattern of fat loss is peripheral rather than central. Importantly, the observed impairment of endothelial function and increase in markers of oxidative stress raise concerns about the widespread use of this agent until further studies demonstrate its cardiovascular safety or otherwise.

## References

1. Peiris AN, Sothmann MS, Hoffmann RG, Hennes MI, Wilson CR, Gustafson AB, Kissebah AH. Adiposity, fat distribution, and cardiovascular risk. *Ann Intern Med.* 1989;110:867-872.
2. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care.* 2001;24:683-689.
3. Bigger JT, Jr., El Sherif T. Polyunsaturated fatty acids and cardiovascular events: a fish tale. *Circulation.* 2001;103:623-625.
4. Hu FB, Stampfer MJ, Manson JE, Rimm EB, Wolk A, Colditz GA, Hennekens CH, Willett WC. Dietary intake of alpha-linolenic acid and risk of fatal ischemic heart disease among women. *Am J Clin Nutr.* 1999;69:890-897.
5. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. *Lancet.* 1999;354:447-455.
6. Wahle KWJ, Heys SD. Conjugated Linoleic Acids (CLA): Are they Ambrosia or Merely a Panacea. Rowett Research Institute - News & Reviews [1], 4-7. 1-12-2001. 1-12-2001.
7. Lee KW, Lee HJ, Cho HY, Kim YJ. Role of the conjugated linoleic acid in the prevention of cancer. *Crit Rev Food Sci Nutr.* 2005;45:135-144.
8. Kritchevsky D, Tepper SA, Wright S, Tso P, Czarnecki SK. Influence of conjugated linoleic acid (CLA) on establishment and progression of atherosclerosis in rabbits. *J Am Coll Nutr.* 2000;19:472S-477S.
9. Ntambi JM, Choi Y, Park Y, Peters JM, Pariza MW. Effects of conjugated linoleic acid (CLA) on immune responses, body composition and stearoyl-CoA desaturase. *Can J Appl Physiol.* 2002;27:617-628.
10. Blankson H, Stakkestad JA, Fagertun H, Thom E, Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. *J Nutr.* 2000;130:2943-2948.
11. Hargrave KM, Li C, Meyer BJ, Kachman SD, Hartzell DL, Della-Fera MA, Miner JL, Baile CA. Adipose depletion and apoptosis induced by trans-10, cis-12 conjugated linoleic Acid in mice. *Obes Res.* 2002;10:1284-1290.
12. Pariza MW, Park Y, Cook ME. Mechanisms of action of conjugated linoleic acid: evidence and speculation. *Proc Soc Exp Biol Med.* 2000;223:8-13.
13. Riserus U, Amer P, Brismar K, Vessby B. Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. *Diabetes Care.* 2002;25:1516-1521.
14. Riserus U, Vessby B, Arnlov J, Basu S. Effects of cis-9,trans-11 conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men. *Am J Clin Nutr.* 2004;80:279-283.
15. Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. *Am J Clin Nutr.* 2004;80:887-895.
16. Basu S, Riserus U, Turpeinen A, Vessby B. Conjugated linoleic acid induces lipid peroxidation in men with abdominal obesity. *Clin Sci (Colch).* 2000;99:511-516.
17. Riserus U, Basu S, Jovinge S, Fredrikson GN, Arnlov J, Vessby B. Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance. *Circulation.* 2002;106:1925-1929.
18. Zambell KL, Keim NL, Van Loan MD, Gale B, Benito P, Kelley DS, Nelson GJ. Conjugated linoleic acid supplementation in humans: effects on body composition and energy expenditure. *Lipids.* 2000;35:777-782.

19. Lohman TG, Roche AF, Martorell R. *Anthropometric Standardization Reference Manual*. Champaign, IL: Human Kinetics; 1991.
20. Nguyen-Duy TB, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat and liver fat are independent predictors of metabolic risk factors in men. *Am J Physiol Endocrinol Metab*. 2003;284:E1065-E1071.
21. Goodfellow J, Bellamy MF, Ramsey MW, Jones CJ, Lewis MJ. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. *J Am Coll Cardiol*. 2000;35:265-270.
22. Misra A, Vikram NK. Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. *Nutrition*. 2003;19:457-466.
23. Hwu CM, Fuh JL, Hsiao CF, Wang SJ, Lu SR, Wei MC, Kao WY, Hsiao LC, Ho LT. Waist circumference predicts metabolic cardiovascular risk in postmenopausal Chinese women. *Menopause*. 2003;10:73-80.
24. Lamarche B. Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. *Coron Artery Dis*. 1998;9:473-481.
25. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinänen-Kiukkaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*. 2001;344:1343-1350.
26. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346:393-403.
27. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. *JAMA*. 2004;292:1440-1446.
28. Vogel RA, Corretti MC, Plotnick GD. The postprandial effect of components of the Mediterranean diet on endothelial function. *J Am Coll Cardiol*. 2000;36:1455-1460.
29. DeLany JP, Blohm F, Truett AA, Scimeca JA, West DB. Conjugated linoleic acid rapidly reduces body fat content in mice without affecting energy intake. *Am J Physiol*. 1999;276:R1172-R1179.
30. Park Y, Albright KJ, Liu W, Storkson JM, Cook ME, Pariza MW. Effect of conjugated linoleic acid on body composition in mice. *Lipids*. 1997;32:853-858.
31. Park Y, Storkson JM, Albright KJ, Liu W, Pariza MW. Evidence that the trans-10,cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. *Lipids*. 1999;34:235-241.
32. Cook ME, Drake B, Jerome D, Pariza MW. The interaction of 9c, 11t/9t, 11c and 10t, 12c conjugated linoleic acid on fat deposition in mice. *Fed Am Soc Exp Biol J*. 1999;13:A1023.
33. Riserus U, Berglund L, Vessby B. Conjugated linoleic acid (CLA) reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic syndrome: a randomised controlled trial. *Int J Obes Relat Metab Disord*. 2001;25:1129-1135.
34. Tsuboyama-Kasaoka N, Takahashi M, Tanemura K, Kim HJ, Tange T, Okuyama H, Kasai M, Ikemoto S, Ezaki O. Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice. *Diabetes*. 2000;49:1534-1542.
35. Clement L, Poirier H, Niot I, Bocher V, Guerre-Millo M, Krief S, Staels B, Besnard P. Dietary trans-10,cis-12 conjugated linoleic acid induces hyperinsulinemia and fatty liver in the mouse. *J Lipid Res*. 2002;43:1400-1409.
36. Poirier H, Rouault C, Clement L, Niot I, Monnot MC, Guerre-Millo M, Besnard P. Hyperinsulinaemia triggered by dietary conjugated linoleic acid is associated with a decrease in leptin and adiponectin plasma levels and pancreatic beta cell hyperplasia in the mouse. *Diabetologia*. 2005.
37. Yamasaki M, Mansho K, Ogino Y, Kasai M, Tachibana H, Yamada K. Acute reduction of serum leptin level by dietary conjugated linoleic acid in Sprague-Dawley rats. *J Nutr Biochem*. 2000;11:467-471.
38. Belury MA, Mahon A, Banni S. The conjugated linoleic acid (CLA) isomer, t10c12-CLA, is inversely associated with changes in body weight and serum leptin in subjects with type 2 diabetes mellitus. *J Nutr*. 2003;133:257S-260S.
39. Houseknecht KL, Vanden Heuvel JP, Moya-Camarena SY, Portocarrero CP, Peck LW, Nickel KP, Belury MA. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty *fafa* rat. *Biochem Biophys Res Commun*. 1998;244:678-682.
40. Yotsumoto H, Hara E, Naka S, Adlof R, Emken E, Yanagita T. 10trans, 12cis-linoleic acid reduces apolipoprotein B secretion in HepG2 cells. *Food Res Int*. 1999;31:403-409.
41. Brown JM, Boysen MS, Jensen SS, Morrison RF, Storkson J, Lea-Currie R, Pariza M, Mandrup S, McIntosh MK. Isomer-specific regulation of metabolism and PPARgamma signaling by CLA in human preadipocytes. *J Lipid Res*. 2003;44:1287-1300.
42. Wargent E, Sennitt MV, Stocker C, Mayes AE, Brown L, O'Dowd J, Wang S, Einerhand AW, Mohede I, Arch JR, Cawthorne MA. Prolonged treatment of genetically obese mice with conjugated linoleic acid improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation. *Lipids Health Dis*. 2005;4:3.
43. Granlund L, Juvet LK, Pedersen JI, Nebb HI. Trans10, cis12-conjugated linoleic acid prevents triacylglycerol accumulation in adipocytes by acting as a PPARgamma modulator. *J Lipid Res*. 2003;44:1441-1452.
44. Kang K, Liu W, Albright KJ, Park Y, Pariza MW. trans-10,cis-12 CLA inhibits differentiation of 3T3-L1 adipocytes and decreases PPAR gamma expression. *Biochem Biophys Res Commun*. 2003;303:795-799.
45. Changhua L, Jindong Y, Defa L, Lidian Z, Shiyan Q, Jianjun X. Conjugated linoleic acid attenuates the production and gene expression of proinflammatory cytokines in weaned pigs challenged with lipopolysaccharide. *J Nutr*. 2005;135:239-244.
46. Smith SA. Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones. *Biochimie*. 2003;85:1219-1230.
47. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. *Diabetes*. 2000;49:749-758.
48. Bots ML, Westerink J, Rabelink TJ, de Koning EJ. Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. *Eur Heart J*. 2005;26:363-368.
49. Smith JC, Evans LM, Wilkinson I, Goodfellow J, Cockcroft JR, Scanlon MF, Davies JS. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. *Clin Endocrinol (Oxf)*. 2002;56:493-501.
50. Evans M, Anderson RA, Smith JC, Khan N, Graham JM, Thomas AW, Morris K, Deely D, Frenneaux MP, Davies JS, Rees A. Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus. *Eur J Clin Invest*. 2003;33:231-238.
51. Quyyumi AA. Prognostic value of endothelial function. *Am J Cardiol*. 2003;91:19H-24H.
52. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. *Diabetes Care*. 2004;27:1487-1495.
53. Truitt A, McNeill G, Vanderhoek JY. Antiplatelet effects of conjugated linoleic acid isomers. *Biochim Biophys Acta*. 1999;1438:239-246.
54. Benito P, Nelson GJ, Kelley DS, Bartolini G, Schmidt PC, Simon V. The effect of conjugated linoleic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. *Lipids*. 2001;36:221-227.
55. Benito P, Nelson GJ, Kelley DS, Bartolini G, Schmidt PC, Simon V. The effect of conjugated linoleic acid on plasma lipoproteins and tissue fatty acid composition in humans. *Lipids*. 2001;36:229-236.

## ADVERSE CARDIOVASCULAR AND CENTRAL NERVOUS SYSTEM EVENTS ASSOCIATED WITH DIETARY SUPPLEMENTS CONTAINING EPHEDRA ALKALOIDS

CHRISTINE A. HALLER, M.D., AND NEAL L. BENOWITZ, M.D.

### ABSTRACT

**Background** Dietary supplements that contain ephedra alkaloids (sometimes called ma huang) are widely promoted and used in the United States as a means of losing weight and increasing energy. In the light of recently reported adverse events related to use of these products, the Food and Drug Administration (FDA) has proposed limits on the dose and duration of use of such supplements. The FDA requested an independent review of reports of adverse events related to the use of supplements that contained ephedra alkaloids to assess causation and to estimate the level of risk the use of these supplements poses to consumers.

**Methods** We reviewed 140 reports of adverse events related to the use of dietary supplements containing ephedra alkaloids that were submitted to the FDA between June 1, 1997, and March 31, 1999. A standardized rating system for assessing causation was applied to each adverse event.

**Results** Thirty-one percent of cases were considered to be definitely or probably related to the use of supplements containing ephedra alkaloids, and 31 percent were deemed to be possibly related. Among the adverse events that were deemed definitely, probably, or possibly related to the use of supplements containing ephedra alkaloids, 47 percent involved cardiovascular symptoms and 18 percent involved the central nervous system. Hypertension was the single most frequent adverse effect (17 reports), followed by palpitations, tachycardia, or both (13); stroke (10); and seizures (7). Ten events resulted in death, and 13 events produced permanent disability, representing 26 percent of the definite, probable, and possible cases.

**Conclusions** The use of dietary supplements that contain ephedra alkaloids may pose a health risk to some persons. These findings indicate the need for a better understanding of individual susceptibility to the adverse effects of such dietary supplements. (N Engl J Med 2000;343:1833-8.)

©2000, Massachusetts Medical Society.

**D**IETARY supplements that contain ephedra alkaloids (also known as ma huang) and guarana-derived caffeine are widely consumed in the United States for purposes of weight reduction and energy enhancement. A number of reports of adverse reactions to dietary supplements that contain ephedra alkaloids, some of which resulted in permanent injury or death, have appeared in the medical literature.<sup>1-6</sup> In response to

growing concern about the safety of ephedra alkaloids in dietary supplements, the Food and Drug Administration (FDA) requested an independent review of reports of adverse events related to the use of ephedra alkaloids to assess causation and determine the level of risk these products pose to consumers.

We conducted an in-depth review of 140 reports of adverse events involving dietary supplements containing ephedra alkaloids that were submitted to the FDA between June 1, 1997, and March 31, 1999, and applied a standardized rating system for assessing causation. We also evaluated factors that might increase the risk to consumers and the adequacy of warnings about potential risks included on product labels. The full report of our review of adverse events is available elsewhere.<sup>7</sup> Here, we summarize our findings.

### METHODS

The objective of the review was to determine the likelihood that ephedra alkaloids (which were usually combined with caffeine) caused the reported adverse events on the basis of the information provided in the FDA MedWatch report, along with supplemental medical records. We independently reviewed each of the 140 cases. Causation was assessed according to the criteria described by Blanc et al.<sup>8</sup> and included an evaluation of the timing of the event in relation to the dose and duration of use of a product; an assessment of the pattern of response to determine whether it constituted a recognized reaction to the substance on the basis of previous reports of ephedrine or similar stimulants in the medical literature; and a determination of the contribution of any underlying diseases or medical conditions.

In general, we defined an adverse event as definitely related to the use of supplements containing ephedra alkaloids only if the symptoms recurred with the reintroduction of ephedra alkaloids or when the onset of symptoms coincided with the expected peak plasma concentration of the drug and resolved within an interval that was consistent with the expected duration of the effect of ephedrine. An adverse event was defined as probably related to the use of supplements containing ephedra alkaloids when the majority of the evidence supported the existence of a causal link but one or more aspects of the case, such as time since the last dose, were unknown or there was a minor inconsistency in the supporting evidence, such as a low reported dose. An adverse event was designated as possibly related to the use of supplements containing ephedra alkaloids when it was equally likely that the adverse event was not related to the use of ephedra alkaloids; for example, in the case of effects that have not been reported in the literature in association with ephedra alkaloids but that are pharmacologically plausible. Reports of ad-

From the Division of Clinical Pharmacology and Experimental Therapeutics, Departments of Medicine and Biopharmaceutical Sciences, University of California, San Francisco, and the California Poison Control System, San Francisco Division — both in San Francisco. Address reprint requests to Dr. Benowitz at the Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco, Box 1220, San Francisco, CA 94143-1220, or at nbeno@itsa.ucsf.edu.

verse events that included scant medical history and incomplete information about the product involved were usually considered to have insufficient information to be assessed. This category was reserved for events in which the evidence was not substantial enough to consider them as possibly related to the use of supplements containing ephedra alkaloids. Adverse events were defined as probably unrelated to the use of supplements containing ephedra alkaloids if the evidence that ephedra alkaloids were the cause was weak or if the likelihood was strong that there was some other cause, either medical or toxicologic. When the scientific evidence or course of events was highly inconsistent with the known effects of ephedra alkaloids, the event was considered definitely unrelated; for example, in the case of symptoms that persisted long after the use of ephedra alkaloids had been discontinued or in the case of symptoms that had no association with the known pharmacodynamic effects of ephedra alkaloids. However, the event was considered related if the patient had a preexisting condition such as hypertension that could have been aggravated by the use of ephedra alkaloids and if the pattern of use met the criteria for causation.

In determining the likelihood of a causal link, we evaluated aspects of the medical history, dietary patterns, and social habits as possible contributing or causative factors. For example, we noted when events occurred while patients were fasting or in conjunction with high intakes of caffeine. We recognized that in the case of adverse events that were most likely not related to the use of supplements containing ephedra alkaloids one or more of the other ingredients in the supplement may have been causally related to the event.

## RESULTS

### Features of the Cases

The age and sex of the users of products containing ephedra alkaloids and the reported reasons for use are shown in Table 1. Although the labels of most such products state that they are not intended for use by persons less than 18 years of age, adverse events were recorded in at least 10 persons under this age. The youngest was 15 years old. Overall, 43 cases (31 percent) were considered to be definitely or probably related to the use of supplements containing ephedra alkaloids, 24 cases (17 percent) were considered to be unrelated to the use of such supplements, 44 cases (31 percent) were deemed possibly related to the use of such supplements, and in 29 cases (21 percent) the information provided was insufficient to assess causation. The types of adverse events that were definitely or probably related to the use of supplements containing ephedra alkaloids and those that were possibly related are summarized in Table 2.

Cardiovascular symptoms made up 47 percent of the adverse events that were definitely, probably, or possibly related to the use of supplements containing ephedra alkaloids. Hypertension was the single most frequent adverse effect, followed by palpitations, tachycardia, or both. Eighteen percent of related and possibly related adverse events involved the central nervous system. Strokes ( $n=10$ ) and seizures ( $n=7$ ) were the most frequent type of central nervous system event reported. The clinical outcomes of the definite, probable, and possible cases are listed in Table 3.

Ten events resulted in death (including 1 neonatal death and 1 fetal death), and 13 events resulted in permanent impairment, which represented 26 percent of

**TABLE 1. AGE AND SEX OF USERS OF SUPPLEMENTS CONTAINING EPHEDRA ALKALOIDS AND REASONS FOR USE, ACCORDING TO ADVERSE-EVENT REPORTS.**

VARIABLE	No. of Users (%)
Age	
<18 yr	10 (7)
18–29 yr	34 (24)
30–45 yr	45 (32)
>45 yr	32 (23)
Unknown	19 (14)
Sex	
Male	56 (40)
Female	84 (60)
Reason for use	
Weight loss	83 (59)
To increase athletic performance	23 (16)
To increase energy	9 (6)
Unknown	24 (17)
Intentional misuse	1 (1)

the definite, probable, and possible cases. Nine serious adverse events occurred in persons who were taking relatively low doses of ephedra alkaloids (range, 12 to 36 mg per day) and who had no important medical risk factors. Features of the definite or probable and possible cases that resulted in death or permanent impairment or that necessitated substantial medical intervention are given in Tables 4 and 5, respectively.

Of the sudden catastrophic cerebrovascular and cardiovascular events, 11 occurred in previously healthy persons. Some of these cases, which were definitely or probably related to the use of supplements containing ephedra alkaloids, are described in detail in the following sections.

### Examples of Severe Cerebrovascular Adverse Events

#### Patient 1

Patient 1 was a healthy 35-year-old woman who had taken aerobic-exercise classes for several years without incident (Table 4). In July 1997, she began taking one capsule of Shape-Fast Plus (according to the label, each capsule contained 15 mg of ephedra alkaloids and 40 mg of caffeine) three times a day before meals for weight loss; she was taking no other medications. She had been taking the product for one week when she collapsed during an aerobics class. Bystanders observed that her arms and legs were flexing and tensing. In the emergency department, her blood pressure was 110/38 mm Hg and the heart rate was 104 beats per minute. A computed tomographic scan of the head showed a subarachnoid hemorrhage. Cerebral angiography showed no evidence of a vascular aneurysm. A urine toxicology screen was positive for amphetamine, a result presumed to reflect a cross-reaction with the ephedrine and therefore to be false positive.

**TABLE 2.** TYPES OF ADVERSE EVENTS THAT WERE DEFINITELY, PROBABLY, OR POSSIBLY RELATED TO THE USE OF SUPPLEMENTS CONTAINING EPHEDRA ALKALOIDS.

ADVERSE EVENT	DEFINITELY OR PROBABLY RELATED (N=43)	POSSIBLY RELATED (N=44)	TOTAL (N=87)
	no. of events (%)		
Cardiovascular			
Hypertension	10 (21)	7 (14)	17 (17)
Palpitations, tachycardia, or both	8 (17)	5 (10)	13 (13)
Arrhythmia	3 (6)	3 (6)	6 (6)
Myocardial infarction	2 (4)	0	2 (2)
Cardiac arrest or sudden death	5 (10)	3 (6)	8 (8)
Central nervous system			
Stroke	4 (8)	6 (12)	10 (10)
Transient ischemic attack	1 (2)	0	1 (1)
Seizure	1 (2)	6 (12)	7 (7)
Other	14 (29)	20 (40)	34 (35)
Total no. of events*	48	50	98

\*The total number of events exceeds the total number of cases, since some cases involved more than one adverse event.

Neurogenic pulmonary edema rapidly developed, necessitating endotracheal intubation and mechanical ventilation. Electrocardiographic findings and cardiac-enzyme levels were consistent with the occurrence of a small myocardial infarction. The treating cardiologist and neurologist thought that ephedrine induced the subarachnoid hemorrhage. The finding of amphetamine on the urine toxicology test supports the presence of ephedrine at the time of the event. Laboratory analysis of the supplement determined that the ephedrine content was 12.0 mg per capsule. At that time, the FDA's recommendation was a maximal dose of 8 mg per serving.<sup>7</sup>

#### Patient 10

Patient 10 was an apparently healthy 39-year-old man who experienced numbness of the right arm and leg on March 17, 1998, 90 minutes after drinking Ultimate Orange, which according to the label contained 415 mg of ma huang (ephedra alkaloids) per serving as well as guarana (a source of caffeine), and 5 minutes after running 3 miles (4.8 km) (Table 4). He also regularly took multivitamins and amino acid supplements, but no other medications. On presentation at a nearby hospital, his blood pressure was 140/78 mm Hg and his pulse was 60 beats per minute. A computed tomographic scan of the head revealed a left-sided intrathalamic hemorrhage. Cerebral angiography showed no evidence of vascular anomalies. The patient had gradual clinical improvement, and his symptoms resolved except for persistent sensory loss on the right side of his face. Chemical analy-

**TABLE 3.** CLINICAL OUTCOMES OF ADVERSE EVENTS THAT WERE DEFINITELY, PROBABLY, OR POSSIBLY RELATED TO THE USE OF SUPPLEMENTS CONTAINING EPHEDRA ALKALOIDS.

OUTCOME	DEFINITELY OR PROBABLY RELATED (N=43)	POSSIBLY RELATED (N=44)	TOTAL (N=87)
	no. of events (%)		
Death	3 (7)	7 (16)	10 (11)
Permanent impairment	7 (16)	6 (14)	13 (15)
Ongoing medical treatment	4 (9)	4 (9)	8 (9)
Full recovery	29 (67)	13 (30)	42 (48)
Unknown	0	14 (32)	14 (16)

sis of the Ultimate Orange product confirmed the presence of ephedrine, as well as of pseudoephedrine, norephedrine, and norpseudoephedrine.

#### Examples of Severe Cardiovascular Adverse Events

##### Patient 2

Patient 2 was a 22-year-old man with a history of asthma who collapsed while lifting weights at a gym on March 31, 1998 (Table 4). His medications included theophylline (Theo-Dur; 300 mg twice daily), albuterol (Ventolin; administered as necessary through a metered-dose inhaler), and a combination of chlorpheniramine maleate, phenylephrine hydrochloride, and phenylpropanolamine hydrochloride (Atrohist Plus SR). According to friends, he had consumed one 18-oz bottle of Ripped Force (which is listed as containing 20 mg of ephedrine alkaloids, 100 mg of caffeine, 250 mg of L-carnitine, and 240 µg of chromium) before working out and was regularly drinking three bottles of Ripped Force per day. He also took creatine and protein supplements. Witnesses reported that he had a seizure. Paramedics initially found him apneic and in ventricular fibrillation. He was successfully resuscitated. Computed tomography of the head showed cerebral edema but no hemorrhage or masses. An initial electrocardiogram showed atrial flutter, which subsequently converted to sinus rhythm. An echocardiogram revealed mild left ventricular hypertrophy. The plasma theophylline level was 11 µg per milliliter (therapeutic range, 10 to 20), and urinalysis revealed 12 µg of ephedrine per milliliter, 0.38 µg of pseudoephedrine per milliliter, and 0.41 µg of phenylpropanolamine per milliliter. The treating cardiologist thought that the combination of ephedra alkaloids and caffeine in Ripped Force and the theophylline and albuterol medications caused a ventric-



**TABLE 4.** OUTCOME IN 11 PATIENTS WITH ADVERSE EVENTS THAT WERE DEFINITELY OR PROBABLY RELATED TO THE USE OF SUPPLEMENTS CONTAINING EPHEDRA ALKALOIDS.

PATIENT No.	AGE (YR)/SEX	NAME OF SUPPLEMENT	ESTIMATED DAILY DOSE OF EPHEDRA ALKALOIDS mg	DURATION OF USE	ADVERSE EVENT	OUTCOME	PREEEXISTING CONDITIONS OR CONCURRENT RISKS
1	35/F	Shape-Fast Plus	45	1 wk	Subarachnoid hemorrhage	Permanent disability	None
2	22/M	Ripped Force	20–60	Unknown	Arrhythmia, cardiac arrest	Permanent disability	Asthma
3	28/F	Herbalife's Thermo-jetics	21	1 day	Cardiac arrest	Permanent disability	None
4	43/M	Ripped Fuel	60	7 mo	Cardiac arrest	Death	Family history of coronary artery disease
5	37/F	Metabolife 356	36	1 wk	Severe hypertension, cardiac arrest, hypokalemia	Death	None
6	59/F	OmniTrim Extra Vitamin-Fortified tea	36	3 wk	Acute myocardial infarction	Coronary bypass surgery	Hypertension
7	38/M	Ripped Fuel	20	1 yr	Arrhythmia, cardiac arrest	Death	None
8	47/F	Total Control	44–66	9 mo	Hypertension, bilateral lacunar infarctions	Permanent disability	Concomitant ingestion of caffeine and ethanol
9	29/M	Ultimate Orange	30	2 wk	Stroke	Permanent disability	Concomitant use of dehydroepiandrosterone and androstenedione
10	39/M	Ultimate Orange	Unknown	Unknown	Hemorrhagic stroke	Permanent disability	None
11	47/M	Purple Blast	Unknown	3 wk	Hemorrhagic stroke	Permanent disability	Possible hypertension

ular arrhythmia that resulted in cardiac arrest. The patient suffered anoxic encephalopathy and remained in a vegetative state for several weeks. After one month in an acute care facility and six weeks at a rehabilitation facility, he was discharged with substantial residual neurologic impairment.

#### Patient 7

Patient 7 was an apparently healthy 38-year-old man who had been taking two capsules of Ripped Fuel (according to the label each capsule contains 10 mg of ephedrine and 100 mg of caffeine) each morning for one year as directed on the product label (Table 4). On June 6, 1996, he took his usual dose along with a cup of coffee and went jogging for 20 minutes. After returning home, he was talking with his family when he suddenly collapsed and appeared to have a tonic-clonic seizure. He had not reported any symptoms before collapsing. He was in full cardiac arrest when paramedics arrived and could not be resuscitated. Autopsy showed mild cardiomegaly with four-chamber dilatation and coronary artery disease, with narrowing of 50 to 75 percent in four vessels. The cause of death was acute arrhythmia resulting from atherosclerotic cardiovascular disease. Subsequent toxicology testing showed blood levels of 110 ng of ephedrine per milliliter (the therapeutic range used for bronchodilation is 20 to 80).<sup>9</sup> An addendum

to the autopsy report included the comment, "ephedrine is a stimulant medication, and as such may have contributed to a fatal arrhythmia in the decedent."

#### DISCUSSION

Ephedrine and related alkaloids have been associated with adverse cardiovascular events, including acute myocardial infarction, severe hypertension, myocarditis, and lethal cardiac arrhythmias.<sup>10,11</sup> Constriction of coronary arteries and, in some cases, vasospasm are believed to be the mechanisms of myocarditis and myocardial infarction. The adrenergic effects of ephedrine shorten cardiac refractory periods, permitting the development of reentrant cardiac arrhythmias. Ephedrine can predispose patients to both hemorrhagic and ischemic stroke.<sup>12</sup> Subarachnoid hemorrhage is thought to be a result of the hypertensive action of ephedrine, which can be short lived, or of cerebral vasculitis, which has been described in association with a variety of sympathomimetic drugs.<sup>13,14</sup> Thrombotic stroke is presumably related to vasoconstriction of large cerebral arteries, which leads to local thrombosis as a result of stasis and sympathomimetic-induced platelet activation.

Caffeine is present in many products that contain ephedra alkaloids, and those who take these products might also be consuming considerable quantities of caffeine in coffee, tea, and soft drinks. Caffeine is like-

**TABLE 5.** OUTCOME IN 15 PATIENTS WITH ADVERSE EVENTS THAT WERE POSSIBLY RELATED TO THE USE OF SUPPLEMENTS CONTAINING EPHEDRA ALKALOIDS.

PATIENT No.	AGE (YR)/SEX	NAME OF SUPPLEMENT	ESTIMATED DAILY DOSE OF EPHEDRA ALKALOIDS mg	DURATION OF USE	ADVERSE EVENT	OUTCOME	PREEXISTING CONDITIONS OR CONCURRENT RISKS
1	46/M	Diet Fuel	Unknown	5–6 mo	Stroke	Death	None
2	22/M	Ripped Fuel	Unknown	Unknown	Hyperthermia, abnormal electrolyte levels, cardiac arrest	Death	None
3	64/F	Fit America Natural Weight Control Aid	Unknown	2 mo	Atrial fibrillation, stroke	Permanent disability	Hypertension, transient ischemic attack
4	47/F	Per-Form Dieter's Natural Tea	Unknown	6 mo	Rhabdomyolysis, hydronephrosis, hypokalemia	Prolonged hospital care	None
5	64/F	Shape-Fast	20	Unknown	Hemorrhagic stroke	Permanent disability	None
6	34/M	Herbalife's Thermo-jetics	Unknown	>3 wk	Atrial flutter, renal failure, hypokalemia, rhabdomyolysis	Death	None
7	32/F	Ripped Fuel	20	4 yr	Premature delivery (34 wk of gestation)	Death of neonate	Smoking
8	29/M	Ultimate Nutrition Product Ma Huang	Unknown	6–7 mo	Stroke	Permanent disability	None
9	15/F	Ripped Fuel	Unknown	2–3 wk	Arrhythmia, cardiac arrest	Death	None
10	41/F	Diet-Phen	12	1 mo	Hypertension, multiple brain-stem infarcts	Permanent disability	Possible hypertension
11	22/F	Magic Herb	72	3 mo	Spontaneous abortion at 9 wk	Death of fetus	None
12	43/F	Metabolife 356	12	6 mo	Severe hypertension, hemorrhagic stroke	Permanent disability	None
13	18/M	Ultimate Orange	Unknown	Unknown	Seizure, hemorrhagic stroke	Death	None
14	61/F	Metabolife 356	24; increased to 60	1 mo	Hypertension, unstable angina	Coronary bypass surgery	Asthma
15	26/M	Ripped Fuel	20–60	3 yr	Status epilepticus, hypokalemia	Permanent disability	None

ly to enhance the cardiovascular and central nervous system effects of ephedrine. Caffeine acts by competitively antagonizing the receptors for adenosine, a hormone released by endothelial cells that dilates blood vessels.<sup>15</sup> By inhibiting adenosine-mediated dilatation of blood vessels, caffeine constricts blood vessels and may increase blood pressure in persons prone to hypertension. Caffeine also augments the release of catecholamines, an effect that, when combined with that of ephedrine, could lead to increased stimulation of the central nervous system and cardiovascular system.<sup>16</sup>

Phenylpropanolamine, another ephedrine alkaloid, was marketed with caffeine in various weight-reducing aids until 1983, when the combination was banned by the FDA after numerous reports of adverse effects. Several studies have shown that caffeine and phenylpropanolamine have an additive effect on blood pressure.<sup>17</sup> These interactions between phenylpropanolamine and caffeine support the idea that the combination of ephedrine and caffeine in a dietary supplement could increase the risk of adverse effects.

The quantity of ephedrine in dietary supplements,

as reported on package labels, is typically about 20 mg per serving, and the usual dose frequency is two to three times per day. These products may contain larger or smaller amounts of ephedra alkaloids than are listed on the product label. For example, 11 of 20 supplements tested by Gurley et al.<sup>18</sup> either failed to list the alkaloid content on the label or had more than a 20 percent difference between the amount listed on the label and the actual amount.

Often, the dose of ephedrine that was associated with an adverse event was less than a typical dose of ephedrine used for bronchodilation (25 to 50 mg). Experimental studies show that ephedrine has only moderate effects on heart rate and blood pressure at these doses.<sup>19,20</sup> The discrepancy between such data and our findings of serious adverse events reported with the use of dietary supplements containing ephedra alkaloids may be due to individual susceptibility, the additive stimulant effects of caffeine, the variability in the contents of pharmacologically active chemicals in the products, or preexisting medical conditions.

Many of the cases we reviewed involved side effects

such as anxiety, tremulousness, insomnia, palpitations, and personality changes that are well known to occur with the use of stimulant drugs. When ephedrine is used for medical purposes, these types of reactions are considered side effects and must be included in the assessment of risks and benefits. In fact, ephedrine is rarely prescribed today for medical purposes, because newer drugs have more specific actions and fewer side effects. The risks of taking ephedra alkaloids as a dietary supplement, however, are difficult to justify because the alkaloids have no demonstrated benefit. Unlike vitamins and minerals, ephedra alkaloid supplements are not essential for proper nutrition. People who take these products to increase their exercise capacity or to lose weight place themselves at risk without a substantial likelihood of benefit.

A limitation to the use of reports of adverse events as an indicator of a product's safety is that the number of people at risk for the event is unknown. Manufacturers of dietary supplements that contain ephedra alkaloids reported that 3 billion servings were sold in 1999.<sup>21</sup> The number of servings that were actually consumed is difficult to determine. Assuming that the products were consumed as directed — three doses per day for 12 weeks — then approximately 12 million people used these supplements in 1999.

Another limitation is that adverse events are known to be underreported. Several studies have shown that spontaneous reporting of adverse events to MedWatch is not routine, and the rate of reporting may be less than 15 percent.<sup>22,23</sup> The frequency of reports of adverse reactions to herbal products is thought to be even lower.<sup>24</sup> Therefore, the frequency of serious adverse events associated with the use of supplements containing ephedra alkaloids cannot be precisely determined with the use of current reporting mechanisms.

Because of the severity of the adverse events that we reviewed and, in particular, the occurrence of events that caused permanent disability and death, we conclude that dietary supplements that contain ephedra alkaloids pose a serious health risk to some users. Although the incidence of serious adverse effects cannot be determined from our analysis, our findings arouse concern about the risks of these products, given that they have no scientifically established benefits. Our findings indicate the need for a better understanding of the determinants of individual susceptibility to the serious adverse effects of dietary supplements containing ephedra alkaloids so that appropriate dosing guidelines and warnings can be devised.

Supported by funds from the Food and Drug Administration and by grants (DA02277 and DA12393) from the National Institute on Drug

Abuse, National Institutes of Health. Dr. Haller was supported by a Veterans Affairs Medical Toxicology fellowship and by a National Research Service Award (T32GM07546) from the National Institutes of Health.

*We are indebted to Dr. Raymond Woosley for his critical review of the manuscript and to Kaye Welch for editorial assistance.*

## REFERENCES

1. Adverse events associated with ephedrine-containing products — Texas, December 1993–September 1995. *JAMA* 1996;276:1711–2.
2. Theoharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink. *J Clin Psychopharmacol* 1997;17:437–9.
3. Josefson D. Herbal stimulant causes US deaths. *BMJ* 1996;312:1378–9.
4. Zalm KA, Li RL, Pursell RA. Cardiovascular toxicity after ingestion of “herbal ecstasy.” *J Emerg Med* 1999;17:289–91.
5. Zaacks SM, Klein L, Tan CD, Rodriguez ER, Leikin JB. Hypersensitivity myocarditis associated with ephedra use. *J Toxicol Clin Toxicol* 1999;37:485–9.
6. Vahedi K, Domigo V, Amarencu R, Bousser MG. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. *J Neurol Neurosurg Psychiatry* 2000;68:112–3.
7. Dietary supplements containing ephedrine alkaloids. FDA docket no. 00N-1200. Rockville, Md.: Food and Drug Administration, 2000. (See [www.accessdata.fda.gov/scripts/oc/ohrms/index.cfm](http://www.accessdata.fda.gov/scripts/oc/ohrms/index.cfm).)
8. Blanc S, Leuenberger P, Berger JP, Brooke EM, Schelling JL. Judgments of trained observers on adverse drug reactions. *Clin Pharmacol Ther* 1979;25:493–8.
9. Costello JE, May CS, Paterson JW, Pickup ME. Pharmacokinetics of ephedrine in asthmatics receiving acute and chronic treatment. *Br J Clin Pharmacol* 1975;2:180–1. abstract.
10. Wiener I, Tilkian AG, Palazzolo M. Coronary artery spasm and myocardial infarction in a patient with normal coronary arteries: temporal relationship to pseudoephedrine ingestion. *Cathet Cardiovasc Diagn* 1990;20:51–3.
11. To LB, Sangster JF, Rampling D, Cammens I. Ephedrine-induced cardiomyopathy. *Med J Aust* 1980;2:35–6.
12. Bruno A, Nolte KB, Chapin J. Stroke associated with ephedrine use. *Neurology* 1993;43:1313–6.
13. Fallis RJ, Fisher M. Cerebral vasculitis and hemorrhage associated with phenylpropanolamine. *Neurology* 1985;35:405–7.
14. Wooten MR, Khangure MS, Murphy MJ. Intracerebral hemorrhage and vasculitis related to ephedrine abuse. *Ann Neurol* 1983;13:337–40.
15. Benowitz NL. Clinical pharmacology of caffeine. *Annu Rev Med* 1990;41:277–88.
16. Robertson D, Frölich JC, Carr RK, et al. Effects of caffeine on plasma renin activity, catecholamines and blood pressure. *N Engl J Med* 1978;298:181–6.
17. Brown NJ, Ryder D, Branch RA. A pharmacodynamic interaction between caffeine and phenylpropanolamine. *Clin Pharmacol Ther* 1991;50:363–71.
18. Gurley BJ, Gardner SF, Hubbard MA. Content versus label claims in ephedra-containing dietary supplements. *Am J Health Syst Pharm* 2000;57:963–9.
19. Drew CD, Knight GT, Hughes DT, Bush M. Comparison of the effects of D-(–)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man. *Br J Clin Pharmacol* 1978;6:221–5.
20. White LM, Gardner SF, Gurley BJ, Marx MA, Wang PL, Estes M. Pharmacokinetics and cardiovascular effects of ma-huang (Ephedra sinica) in normotensive adults. *J Clin Pharmacol* 1997;37:116–22.
21. Dietary supplement market view. Chevy Chase, Md.: FDC Reports, August 2000.
22. Chyka PA, McCommon SW. Reporting of adverse drug reactions by poison control centres in the US. *Drug Saf* 2000;23:87–93.
23. Spontaneous adverse event reports. (See <http://www.fda.gov/ohrms/dockets/ac/99/slides/3558slc/tsld003.htm>.)
24. Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. *Br J Clin Pharmacol* 1998;45:496–500.